View Filing Data

Document and Entity Information	12 Months Ended
Document and Entity Information	Mar. 31, 2019 shares
Document And Entity Information [Abstract]
Entity Registrant Name	PORTAGE BIOTECH INC.
Entity Central Index Key	0001095435
Document Type	20-F
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity a Well-known Seasoned Issuer	No
Entity's Reporting Status Current	No
Entity a Voluntary Filer	No
Entity Ex Transition Period	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	1,085,789,986
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Incorporation State Country Code	A6
Entity Interactive Data Current	No
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Current
Cash and cash equivalents	$ 6,166	$ 7,520
Prepaid expenses and other receivable	282	44
Investment in marketable equity securities	103	52
Total current	6,551	7,616
Long-term assets
Long term portion of other receivable	45	56
Convertible note receivable		950
Investment in associate	1,207	681
Investments in private companies	5,200	700
Goodwill	43,324
In-process research and development	117,388
Total assets	173,715	10,003
Current liabilities
Accounts payable and accrued liabilities	1,107	127
Unsecured notes payable	663
Warrant liability	24	24
Total current liabilities	1,794	151
Non-current liabilities
Unsecured notes payable	3,000	233
Deferred tax liability	20,364
Total non-current liablities	23,364	233
Total liabilities	25,158	384
Equity
Capital stock	116,237	23,654
Stock option reserve	324	267
Accumulated other comprehensive income	82	32
Accumulated deficit	(16,969)	(14,334)
Total equity attributable to owners of the Company	99,674	9,619
Non-controlling interest	48,883
Total equity	148,557	9,619
Total liabilities and equity	173,715	10,003
Commitments and Contingencies (Note 17)

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Expenses
Research and development	$ 762	$ 561	$ 32,450
Consulting fees	1,621	1,335	1,923
Professional fees	247	215	634
Other operating costs	134	124	492
Loss from operations	(2,764)	(2,235)	(35,499)
Realized gain on investment in Biohaven Pharmaceuticals Holding Company Ltd. (Biohaven)		126,000
Gain on restating retained interest in associate at fair value			49,864
Share of losses of associates accounted for using equity method	(162)		(14,461)
Foreign exchange transaction loss	(691)
Interest income	111
Interest expense	(88)	(24)	(545)
Net (loss) income	(3,594)	123,741	(641)
Other comprehensive income
Realized gains transferred to retained earnings upon disposal of investment		(24,515)
Unrealized gain on investment in Biohaven	50		24,547
Total comprehensive (loss) income for year	(3,544)	99,226	23,906
Net (loss) income attributable to:
Owners of the Company	(2,217)	123,741	16,299
Non-controlling interest	(959)		(16,940)
Net (loss) income	(3,594)	123,741	(641)
Comprehensive (loss) income attributable to:
Owners of the Company	(2,585)	99,226	40,846
Non-controlling interest	(959)		(16,940)
Total comprehensive (loss) income for year	$ (3,544)	$ 99,226	$ 23,906
Basic and diluted (loss) income per share
Basic	$ (0.00)	$ 0.46	$ 0.06
Diluted	$ 0.00	$ 0.46	$ 0.06
Weighted average shares outstanding
Basic	481,987	267,796	254,053
Diluted	481,987	269,642	272,193

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Capital Stock	Stock Option Reserve	Warrants	Accumulated other comprehensive income	Retained Earnings (Accumulated Deficit)	Equity Attributable to Owners of Company	Non-controlling Interests	Total
Balance at Mar. 31, 2016	$ 17,055	$ 5,076	$ 2,756		$ (14,618)	$ 10,269	$ 2,060	$ 12,329
Balance, shares at Mar. 31, 2016	253,439
Statement Line Items [Line Items]
Share based compensation		404				404		1,697
Value of shares issued as compensation	$ 1,305					1,305		1,305
Value of shares issued as compensation, shares	7,250
Unrealized gain on investment in Biohaven				24,547		24,547		24,547
Loss of control of subsidiary		(3,774)	(2,756)		13,300	6,770	14,880	21,650
Net income (loss) for year					16,299	16,299	(16,940)	(641)
Balance at Mar. 31, 2017	$ 18,360	1,706		24,547	14,981	59,594		59,594
Balance, shares at Mar. 31, 2017	260,689
Statement Line Items [Line Items]
Share based compensation		193				193		1,129
Options exercised	$ 4,358	(1,632)				2,726		2,726
Options exercised, shares	18,471
Value of shares issued as compensation	$ 936					936		936
Value of shares issued as compensation, shares	1,560
Realized gain transferred to income on disposition of Biohaven shares by sale and stock dividend				(24,515)		(24,515)		(24,515)
Stock dividend of Biohaven shares					(153,056)	(153,056)		(153,056)
Net income (loss) for year					123,741	123,741		123,741
Balance at Mar. 31, 2018	$ 23,654	267		32	(14,334)	9,619		9,619
Balance, shares at Mar. 31, 2018	280,720
Statement Line Items [Line Items]
Share based compensation		57				57	1,111	1,148
Unrealized gain on investment in Biohaven				50		50		50
Shares issued on acquisition of SalvaRx Ltd.	92,583					92,583		92,583
Shares issued on acquisition of SalvaRx Ltd., shares	805,070
Fair value of acquired subsidiaries attributable to non-controlling interest on acquisition							48,731	48,731
Net income (loss) for year					(2,635)	(2,635)	(959)	(3,594)
Balance at Mar. 31, 2019	$ 116,237	$ 324		$ 82	$ (16,969)	$ 99,674	$ 48,883	$ 148,557
Balance, shares at Mar. 31, 2019	1,085,790

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities
Net (loss) income for year	$ (3,594)	$ 123,741	$ (641)
Adjustments for non-cash items:
Share based compensation expensed as consulting fee	1,148	1,129	1,697
Realized gain on investment, available for sale		(126,000)
Change in fair value of warrant liability classified within interest		7
Gain on investment at date of loss of control of subsidiary			(49,863)
Share of losses of associates accounted for using equity method	162		14,461
Share based compensation expensed as research and development	20		12
Foreign exchange transaction loss	691
Subsidiary's expenses to date of deconsolidation			33,064
Net change in working capital components
Prepaid expenses and other receivable	352	32	140
Accounts payable and accrued liabilities	363	18	(191)
Net cash flows from operating activities	(858)	(1,073)	(1,321)
Cash flows from investing activities
Cash from SalvaRx acquisition (note 10)	1,192
Cash retained by on deconsolidated subsidiary			(3,409)
Proceeds from sale of investment, available for sale		7,289
Investment in associate	(688)	(681)
Purchase of notes receivable issued by SalvaRx Ltd. prior to the acquisition by Portage	(950)	(950)
Net cash flows from investing activities	(446)	5,658	(3,409)
Cash flows from financing activities
Proceeds from exercise of stock options		2,726
Proceeds from issuance/(repayment) of notes payable	(50)	50	200
Net cash flows from financing activities	(50)	2,776	200
(Decrease) Increase in cash and cash equivalents during year	(1,354)	7,361	(4,530)
Cash and cash equivalents at beginning of year	7,520	159	4,689
Cash and cash equivalents at end of year	6,166	7,520	159
Supplemental disclosures of non-cash investing and financing activities
Fair value of shares issued to acquire SalvaRx Ltd.	92,583
Unrealized gain on investment in Biohaven	50
Effective settlement of convertible notes issued by SalvaRx Ltd. upon acquisition by Portage	1,963
Fair value of Biohaven shares distributed as a property dividend		$ 177,571

Nature of Operations

12 Months Ended

Mar. 31, 2019

Nature of Operations [Abstract]

Nature of Operations

1.	NATURE OF OPERATIONS

Portage Biotech Inc. (the "Company") is incorporated in the British Virgin Islands ("BVI") with its registered office located at FH Chambers, P.O. Box 4649, Road Town, Tortola, BVI. Its Toronto agent, Portage Services Ltd., is located at 47 Avenue Road, Suite 200, Toronto, Ontario, M5R 2G3, Canada.

The Company is a reporting issuer with the Ontario Securities Commission on the Canadian Stock Exchange under the symbol PBT-U and US Securities and Exchange Commission on the OTC market under the symbol PTGEF.

The Company is engaged in the business of researching and developing pharmaceutical and biotechnology products through to clinical "proof of concept" with an initial focus on unmet clinical needs. Following proof of concept, the Company seeks to sell or license the products to large pharmaceutical companies for further development and commercialization.

Recent Developments:

On August 13, 2018, the Company reached a definitive agreement to acquire 100% of SalvaRx Limited ("SalvaRx") in exchange for 805,070,067 common shares of the Company (the "SalvaRx Acquisition"). The SalvaRx Acquisition was completed on January 8, 2019 (the "Acquisition Date") upon receiving shareholder and regulatory approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx's five investees and subsidiaries: IOX Therapeutics Ltd ("IOX"), Nekonal Oncology Limited ("Nekonal"), Intensity Therapeutics Inc. ("Intensity"), Saugatuck Therapeutics Ltd. ("Saugatuck") and Rift Biotherapeutics Inc ("Rift"). In connection with the SalvaRx Acquisition, the Company also acquired an option in Nekonal SARL, a Luxembourg-based company holding intellectual property rights for therapeutics and diagnostics in the field of autoimmune disorders and oncology, to participate in the funding of its autoimmune programs. See Notes 2 (b) and 10.

Liquidity and Capital Resources:

The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of March 31, 2019, the Company had cash of approximately $6.2 million, working capital of approximately $4.8 million and an accumulated deficit of approximately $17.0 million.

The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company's ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances would result in dilution to its existing stockholders and any future debt securities may contain covenants that limit the Company's operations or ability to enter into certain transactions.

The Company's current cash is sufficient to fund operations for at least the next 12 months because the Company extended the maturity date of $3.4 million of principal and interest on the SalvaRx Notes to 2021 and can defer discretionary research and development and cash compensation by approximately $1.4 million. However, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to develop and seek regulatory approvals for the Company's existing and new product candidates. If such funding is not available or not available on terms acceptable to the Company, the Company's current development plan and plans for expansion of its general and administrative infrastructure may be curtailed.

Basis of Presentation

12 Months Ended

Mar. 31, 2019

Basis of Presentation [Abstract]

Basis of Presentation

2.	BASIS OF PRESENTATION

(a)

Statement of Compliance and Basis of presentation

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB"), and interpretations of the International Financial Reporting Interpretations Committee. Certain reclassifications have been made to prior years to conform with current year presentation.

These consolidated financial statements have been prepared on a historical cost basis except for items disclosed herein at fair value (see Note 20).

The Company has only one reportable operating segment.

These consolidated financial statements were approved and authorized for issuance by the Audit Committee and Board of Directors on December 23, 2019.

(b)

Consolidation

The consolidated financial statements include the accounts of the Company and,

Portage Services Ltd., a wholly-owned subsidiary incorporated in Ontario on January 31, 2011.

Portage Pharmaceuticals Ltd. ("PPL") a wholly-owned subsidiary resulting from a merger on July 23, 2013 and is incorporated under the laws of the British Virgin Islands, as a BVI business company.

EyGen Limited, ("EyGen") which is a wholly-owned subsidiary of PPL, was incorporated on September 20, 2016 under the laws of the BVI.

SalvaRx Limited ("SalvaRx"), a wholly-owned subsidiary, incorporated on May 6 2015 in the British Virgin Islands.

Portage Glasgow Ltd ("PGL"), a 65% subsidiary of PPL, incorporated in Glasgow, Scotland.

IOX, a United Kingdom based immune-oncology company, a 60.49% subsidiary incorporated in the United Kingdom on February 10, 2015.

Saugatuck, a 70% owned subsidiary incorporated in the British Virgin Islands.

All inter-company balances and transactions have been eliminated on consolidation.

Non-controlling interest in the equity of a subsidiary is accounted for and reported as a component of stockholders' equity. Non-controlling interest represents the 39.51% shareholder ownership interest in IOX and the 30% shareholder ownership interest in Saugatuck which are consolidated by the Company.

(c)

Functional and presentation currency

The majority of the Company's functional and presentation currency is US Dollars.

(d)

Use of Estimates and judgments

The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Significant areas where estimates are made include valuation of financial instruments, research and development costs, fair value used for acquisition and measurement of share- based compensation. Significant areas where critical judgments are applied include assessment of impairment of investments and the determination of the accounting acquirer and acquiree in the business combination accounting.

Significant Accounting Policies

12 Months Ended

Mar. 31, 2019

Significant Accounting Policies [Abstract]

Significant Accounting Policies

3.	SIGNIFICANT ACCOUNTING POLICIES

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, which have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below:

Financial instruments

i) Financial assets

Classification

Upon the initial recognition of a financial assets, the financial assets are classified as one of the following measurement methodologies: (a) amortized cost, (b) fair value through other comprehensive income (FVTOCI), or (c) fair value through profit or loss (FVTPL). Subsequent measurement will be based on the initial classification of the financial assets.

The classification of a financial asset at initial recognition depends on the Company's business model for managing the financial asset and the financial asset's contractual cash flow characteristics.

In order for a financial asset to be measured at amortized cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level.

The Company's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both.

Measurement

For purposes of subsequent measurement, financial assets are classified in three categories:

Financial assets at amortized cost (debt instruments)

Financial assets at FVTOCI

Financial assets at FVTPL

Financial assets at amortized cost (debt instruments)

The Company measures financial assets at amortized cost if both of the following conditions are met:

The financial asset is held within a business model with the objective of holding the financial asset in order to collect contractual cash flows and;

The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding

Financial assets at amortized cost are subsequently measured using the effective interest rate method and are subject to a period impairment review. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired.

The Company's financial assets classified at amortized cost includes other receivable and convertible note receivable (see Note 5).

Financial assets designated at fair value through OCI (equity instruments)

Upon initial recognition, the Company can elect to classify irrevocably its equity investments as equity instruments designated at FVTOCI when they meet the definition of equity under IAS 32 Financial Instruments: Presentation and are not held for trading. The classification is determined on an instrument-by-instrument basis.

Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the statement of profit or loss when the right of payment has been established, except when the Company benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.

The Company irrevocably elected to classify its investments in Biohaven Pharmaceuticals Holding Company ltd (Biohaven), Sentien and Intensity as FVTOCI.

Financial assets at fair value through profit or loss

Financial assets at FVTPL include financial assets held for trading, financial assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified and measured FVTPL, irrespective of the business model.

Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss.

ii) Financial liabilities

The Company's financial liabilities include accounts payable which approximates fair value due to their short maturity and unsecured notes payable assumed in the SalvaRx Acquisition. The unsecured notes payable assumed in the SalvaRx Acquisition are recorded at fair value on the acquisition date. (see Notes 10 and 12).

Warrant liability and note payable

During the year ended March 31, 2017, the Company's subsidiaries, PPL and EyGen, issued notes with warrants (see Note 12). The warrants which are exercisable for common shares of PPL and EyGen respectively.

Accordingly, at inception a portion of the proceeds was allocated to the fair value of the warrants and the remainder is recorded as a note payable.

At subsequent balance sheet dates the fair value of the warrant is remeasured with movements in the fair value recorded in profit or loss. The loan is recorded at amortized cost and is accounted for using the effective interest method.

In connection with the acquisition of SalvaRx (see Notes 10 and 12), the Company acquired notes payable and associated warrants which were recorded at fair value on the date of the acquisition.

Impairment of financial assets

IFRS 9 requires the Company to recognize an allowance for expected credit losses ("ECLs") for all debt instruments and investments not held at fair value through profit or loss and contract assets. For intangible assets, at the end of each reporting period and whenever there is an indication that the intangible asset may be impaired, the Company reviews the carrying amounts of its intangible assets to determine whether there is any indication that those assets have suffered an impairment loss.

The Company assessed at the end of each reporting period whether there was objective evidence that a financial asset was impaired. The Company recognizes an allowance for ECLs for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

Foreign currencies

The functional and presentation currency of the Company and its subsidiaries (note 2(b)) is the US dollar. Monetary assets and liabilities are translated at exchange rates in effect at the balance sheet date. Non-monetary assets are translated at exchange rates in effect when they were acquired. Revenue and expenses are translated at the approximate average rate of exchange for the period. Foreign currency differences arising on retranslation are recognized in income or loss.

The effect of exchange rates on our foreign currency-denominated asset and liability balances are recorded as foreign currency transaction losses in the determination of net income (loss).

Cash and cash equivalents

Cash and cash equivalents comprise cash in hand and on-demand deposits that are readily convertible to a known amount of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. The Company does not have any cash equivalents for the years ended March 31, 2019 and 2018.

Intangible assets acquired in business combinations

Intangible assets acquired in business combinations that are separable from goodwill are recorded at their acquisition date fair value. Subsequent to initial recognition, intangible assets acquired in business combinations are reported net of accumulated amortization and any impairment losses.

Impairment of indefinite life intangible assets other than goodwill

At the end of each annual reporting period and whenever there is an indication that an indefinite life intangible asset may be impaired, the Company reviews the carrying amounts of such intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated to determine the extent of impairment loss (if any). When it is not possible to estimate the recoverable amount of any individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units ("CGU" or "CGUs"), or the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

Share-based payments

The Company determines the fair value of share-based payments granted to directors, officers, employees and consultants using the Black-Scholes option-pricing model at the grant date. Assumptions for the Black-Scholes model are determined as follows:

	●	Expected Volatility. The expected volatility rate used to value stock option grants is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry.

	●	Expected Term. The Company used historical experience.

	●	Risk-free Interest Rate. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of the Company's stock option grants.

●

Expected Dividend Yield. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future.

Share-based payments to employees, officers and directors are recorded and reflected as an expense over the vesting period with a corresponding increase in the stock option reserve. On exercise, the associated amounts previously recorded in the stock option reserve are transferred to common share capital.

(Loss) Income per Share

Basic (loss) income per share is calculated by dividing net (loss) income (the numerator) by the weighted average number of common shares outstanding (the denominator) during the period. Diluted (loss) Income per share reflects the dilution that would occur if outstanding stock options and share purchase warrants were exercised into common shares using the treasury stock method and convertible debt were converted into common shares using the if-converted method. Diluted (loss) income per share is calculated by dividing net (loss) income applicable to common shares by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued.

The inclusion of the Company's stock options and share purchase warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share (see

Note 16).

Investment in private companies

The investment is comprised of shares of private companies that have been acquired through a private placement. The investment is initially recorded at fair value. Following acquisition, the Company evaluates whether control or significant influence is exerted by the Company over the affairs of the investee company. Based on the evaluation, the Company accounts for the investment using either the consolidation, equity accounting or fair value method. See Note 9.

Investments in associates and joint ventures

An associate is an entity over which the Company has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies.

A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.

The results and assets and liabilities of associates and joint ventures are incorporated in these consolidated financial statements using the equity method of accounting, except when the investment, or a portion thereof, is classified as held for sale, in which case it is accounted for in accordance with IFRS 5. Under the equity method, an investment in an associate or a joint venture is initially recognized in the consolidated statement of financial position at cost from the date the investee becomes an associate or a joint venture and adjusted thereafter to recognize the Company's share of the profit or loss and other comprehensive income of the associate. When the Company's share of losses of an associate or a joint venture exceed the Company's interest in that associate or joint venture (which includes any long-term interests that, in substance, form part of the Company's net investment in the associate or joint venture), the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that

The Company has incurred legal or constructive obligations or made payments on behalf of the associate or joint venture.

After application of the equity method, the Company determines whether it is necessary to recognize an impairment loss on its investment in its associate or joint venture. At each reporting date, the Company determines whether there is objective evidence that the investment in the associate or joint venture is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate or joint venture and its carrying value, and then recognizes the loss within 'Share of profit of an associate and a joint venture' in the statement of profit or loss.

Research and Development Expenses

(i)

Research and development

Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is expensed as incurred.

Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically, and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization. Amortization of the asset begins when development is complete and the asset is available for use. It is amortized over the period of expected future benefit. During the period of development, the asset is tested for impairment annually.

Research and development expenses include all direct and indirect operating expenses supporting the products in development.

(ii)

Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures are recognized in income or loss as incurred.

(iii)

Clinical trial expenses

Clinical trial expenses are a component of the Company's research and development costs. These expenses include fees paid to contract research organizations, clinical sites, and other organizations who conduct development activities on the Company's behalf. The amount of clinical trial expenses recognized in a period related to clinical agreements are based on estimates of the work performed using an accrual basis of accounting. These estimates incorporate factors such as patient enrolment, services provided, contractual terms, and prior experience with similar contracts.

Contingent liability

A contingent liability is a possible obligation that arises from past events and of which the existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not within the control of the Corporation; or a present obligation that arises from past events (and therefore exists), but is not recognized because it is not probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation; or the amount of the obligation cannot be estimated reliably.

Determination of fair value

A number of the Company's accounting policies and disclosures required the determination of fair value, both for financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. When applicable, further information about the assumptions made in determining fair values is disclosed in Note 20 and other footnotes that specifically relate to assets or liabilities measured at fair value.

Income Tax

The Company uses the asset and liability method to account for income taxes. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities for accounting purposes, and their respective tax bases.

Deferred income tax assets and liabilities are measured using tax rates that have been enacted or substantively enacted and applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and are reviewed at the end of each reporting period.

Business Combinations

Business combinations are accounted for using the acquisition method as of the date when control transfers to the Company. The total purchase price less the fair value of non-controlling interest is allocated to the acquired net tangible and intangible assets and liabilities assumed at fair value.

Transaction costs that the Company incurs in connection with a business combination are expensed as incurred.

Goodwill

Goodwill represents the excess of the purchase price paid for the acquisition of an entity and the amount recognized for non-controlling interests over the fair value of the net identifiable assets acquired and liabilities assumed. Goodwill is allocated to the CGUs which are expected to benefit from the synergies of the combination. Goodwill is not subject to amortization and is tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.

Impairment is determined for goodwill by assessing if the carrying value of a CGU, including the allocated goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs to sell and the value in use. Impairment losses recognized in respect of a CGU are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGU. Any goodwill impairment is recorded in income in the period in which the impairment is identified. Impairment losses on goodwill are not subsequently reversed.

Adoption of New Standards

IFRS 9 - Financial Instruments

On January 1, 2018, the Company adopted IFRS 9 "Financial Instruments", which replaces IAS 39, "Financial Instruments: Recognition and Measurement". IFRS 9 introduces new requirements on how an entity should classify and measure financial assets, financial liabilities, replaces the rules for impairment of financial assets, and amends the requirements for hedge accounting. The standard also requires entities to provide users of financial statements with more informative and relevant disclosures. As a result of adopting IFRS 9, the Company's investment in Sentien, a private company, was required to be measured at fair value. IFRS 9 contains guidance on when cost may be the best estimate of fair value and also when it might not be representative of fair value. The Company has irrevocably elected to present fair value gains and losses on its private investments in OCI, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognized in profit or loss. At transition its private company investment was transferred from a measurement basis of cost to fair value through OCI, there was no impact as the private investments cost approximated its fair value upon adoption. The Company did not have any other material impacts upon adoption. Therefore, no cumulative effect adjustment has been made to the opening balance of the accumulated deficit.

New standards and interpretations not yet adopted

Standards issued but not yet effective up to the date of issuance of the Company's consolidated financial statements are listed below. This listing is of standards and interpretations issued which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they become effective.

IFRS 16, Leases

In January 2016, the IASB issued IFRS 16 which requires lessees to recognize assets and liabilities for most leases. Lessees will have a single accounting model for all leases, with certain exemptions. The new standard is effective for annual reporting periods beginning on or subsequent to January 1, 2019, with limited early application permitted. The new standard permits lessees to use either a full retrospective or a modified retrospective approach on transition for leases existing at the date of transition, with options to use certain transition reliefs. The adoption of this standard will not have a material impact on the Company's financial statements.

IFRIC 23 Uncertainty over Income Tax Treatment

The interpretation addresses the determination of taxable income (tax loss), tax bases, unused tax losses, unused tax credits and tax rates, when there is uncertainty over income tax treatments under IAS 12. The new standard is effective to annual reporting periods beginning on or after January 1, 2019. The Company does not believe that the above standard will have any impact on its financial statements.

Prepayment Features with Negative Compensation (Amendments to IFRS 9)

Amends the existing requirements in IFRS 9 regarding termination rights in order to allow measurement at amortized cost (or, depending on the business model, at fair value through other comprehensive income) even in the case of negative compensation payments. The amendment is effective to annual reporting periods beginning on or subsequent to January 1, 2019. The Company does not believe that the above standard will have any impact on its financial statements.

Long-term Interests in Associates and Joint Ventures (Amendments to IAS 28)

Clarifies that an entity applies IFRS 9 Financial Instruments to long-term interests in an associate or joint venture that form part of the net investment in the associate or joint venture but to which the equity method is not applied. The amendment is effective to annual reporting periods beginning on or subsequent to January 1, 2019. The adoption of this standard will not impact the Company's financial statements as all associates and joint ventures use the equity method.

Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture

The amendment addresses the conflict between IFRS 10 and IAS 28 in dealing with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely, but an entity that early adopts the amendments must apply them prospectively. The Company does not believe that the above amendment will have any material impact on its financial statements.

Amendments to IAS 23 Borrowing Costs: Annual Improvements to IFRS 2015 – 2017 Cycle

The amendment specifies that when determining the weighted average borrowing rate for purposes of capitalizing borrowing costs, the calculation excludes borrowings which have been made specifically for the purposes of obtaining a qualifying asset, but only until substantially all the activities necessary to prepare the asset for its intended use or sale are complete. The new standard is effective to annual reporting periods beginning on or subsequent to January 1, 2019. The Company does not believe that the above amendment will have any impact on its financial statements.

Amendments to IAS 12 Income Taxes: Annual Improvements to IFRS 2015 – 2017 Cycle

The amendment specifies that the income tax consequences on dividends are recognized in profit or loss, other comprehensive income or equity according to where the entity originally recognized the events or transactions which generated the distributable reserves. The new standard is effective to annual reporting periods beginning on or subsequent to January 1, 2019. The Company does not believe that the above amendment will have any impact on its financial statements.

Amendments to IFRS 3: Business Combinations: Annual Improvements to IFRS 2015 – 2017 Cycle

The amendment clarifies that, when an entity obtains control of a business that is a joint operation, it applies the requirements for a business combination achieved in stages, including remeasuring previously held interests in the assets and liabilities of the joint operation at fair value. In doing so, the acquirer remeasures its entire previously held interest in the joint operation. The new standard is effective to annual reporting periods beginning on or subsequent to January 1, 2019. The Company does not believe that the above amendment will have any impact on its financial statements.

Prepaid Expenses and Other Receivable

12 Months Ended

Mar. 31, 2019

Prepaid Expenses and Other Receivable [Abstract]

PREPAID EXPENSES AND OTHER RECEIVABLE

4.	PREPAID EXPENSES AND OTHER RECEIVABLE

	2019		2018
Year ended March 31,	in 000'$		in 000'$
Prepaid expenses		19		16
R&D credits		208		-
Other receivables		55		28
	$	282	$	44

In October 2016, the Company's wholly-owned subsidiary, PPL agreed to a settlement of $120,000 for a claim made against a supplier. As of March 31, 2019, the Company received $63,750. The remaining balance is payable in five annual instalments of $11,250. Accordingly, $11,250 is classified as a current asset within other receivables and the non-current portion of $45,000 is classified as a long-term asset ($56,250 classified as a long-term asset and $11,250 classified as a current asset as at March 31, 2018).

Convertible Note Receivable

12 Months Ended

Mar. 31, 2019

Convertible Note Receivable [Abstract]

CONVERTIBLE NOTE RECEIVABLE

5.	CONVERTIBLE NOTE RECEIVABLE

On March 7, 2018, the Company invested $950,000 in a convertible notes (the "Notes") issued by IOX in U.S. dollars. On December 3, 2018, the Company invested an additional $950,000 in IOX. The Notes carry interest at 7% accruing daily and mature within twelve months of their issuance. The Company can convert the notes and accrued interest into ordinary shares of IOX at any time before maturity at £120 per share. There is an automatic conversion on a qualifying event, being IOX raising $2 million or a sale of the Company per the agreement. Conversion price will be the price at which the money was raised discounted by 25%. IOX has the right to repay the Notes together with accrued interest at any time.

As a result of the SalvaRx Acquisition, IOX has become a subsidiary of the Company during the year ended March 31, 2019. In accordance with IFRS 3 – Business combinations, the fair value, including interest receivable, of the Notes are effectively settled upon the business combination and the fair value of the Notes is additional consideration (see Notes 10 and 12). The Company utilized a Monte Carlo Simulation model, which incorporates significant inputs that are not observable in the market, and thus represents a Level 3 measurement. The unobservable inputs utilized for measuring the fair value of the of the Notes reflect management's own assumptions about the assumptions that market participants would use in valuing the Notes as of the acquisition date. The Company determined the fair value of the Notes of approximately $2.0 million by using the following key inputs to the Monte Carlo Simulation Model:

Risk free discount rate	3	%
Risk free interest rate	1	%
Volatility	80	%
Dividend yield	Nil

Investment in Biohaven

12 Months Ended

Mar. 31, 2019

Investment in Biohaven [Abstract]

INVESTMENT IN BIOHAVEN

6.	INVESTMENT IN BIOHAVEN

As of February 15, 2017, the Company held 6,341,500 shares of Biohaven Pharmaceutical Holdings Company Ltd. ("Biohaven") that is being accounted for as available for sale securities following its loss of control, as a subsidiary.

The Company currently accounts for its investment in Biohaven as a financial asset classified as FVTOCI. Biohaven is listed and began trading on New York Stock Exchange effective May 4, 2017.

On January 16, 2018, the Company distributed 6,102,730 shares of its Biohaven stock as a property dividend, on a pro-rata basis, to the shareholders of the Company's ordinary shares. The Company's ordinary shareholders of Portage ordinary shares received one (1) common share of Biohaven as a dividend for each forty-six (46) outstanding ordinary shares of the Company owned as of January 5, 2018, the Record Date. No fractional shares, or cash in lieu of fractional shares, were distributed. In accordance with IFRIC 17.

Between January 3, 2018 and February 1, 2018, the Company sold 236,770 of the Biohaven shares in the open market for an average price of $30.79 per share for total proceeds of $7.3 million.

As at March 31, 2019 and 2018, the fair value of the 2,000 share investment in Biohaven was $102,940 (at a quoted market price of $51.47 per share) and $52,520 (at a quoted market price of $25.76 per share), respectively. The unrealized gain of $50,420 is included in unrealized gain on investment in Biohaven in the accompanying statement of operations and other comprehensive income (loss) for the year ended March 31, 2019.

The following table is a rollforward of the investment in Biohaven as of March 31, 2108 and 2019 (in 000's):

Balance at March 31, 2017	$	58,913
Realized gain on investment		126,000
Realized gain transferred to income on disposition of shares		(24,515	)
Proceeds from sale of investment		(7,289	)
Property dividend of Biohaven shares		(153,056	)
Balance at March 31, 2018		53
Unrealized gain on investment		50
Balance at March 31, 2019	$	103

Investment in Associate

12 Months Ended

Mar. 31, 2019

Investment in Associate [Abstract]

INVESTMENT IN ASSOCIATE

7.	INVESTMENT IN ASSOCIATE

The following table is a rollforward of the investment Stimunity S.A. as of March 31, 2108 and 2019 (in 000's):

As at April 1, 2017	$	-
Initial investment		681
Share of losses		-
As at March 31, 2018		681
Additional investment		688
Share of losses		(162	)
As at March 31, 2019	$	1,207

Details of the Company's associate as of March 31, 2019 and 2018 are as follows:

Name

Principal Activity

Place of Incorporation and principal place of business

Voting rights held as at March 31, 2019

Voting rights held as at March 31, 2018

Associate:

Stimunity S.A.

Biotechnology

Paris, France

36.5

27.4

The abovementioned associate is accounted for using the equity method in these consolidated financial statements.

On February 28, 2018, the Company made an initial investment of €0.5 million ($0.7 million) by subscribing to 3,780 new Class A shares of Stimunity SAS ("Stimunity"), a French simplified joint stock company located and operating in Paris, France, for a 27% equity interest. One of the three directors on the Board of Directors is represented by Portage. The management of Stimunity is controlled by the two other founding shareholders of Stimunity. Management has evaluated the Company's investment and concluded that Portage has significant influence and therefore its investment in Stimunity is accounted for using the equity method.

Portage also committed to a second investment in the amount of €1.5 million ($1.9 million) (the "Stimunity Commitment") by subscribing to 4,140 new ordinary shares at a price of €363 per share, upon Stimunity successfully completing agreed milestones (the "Milestones"). On March 25, 2019, the Company made an additional discretionary investment of €0.6million ($0.7 million) by subscribing to 1,945 ordinary shares at a price of €308.55 per share, increasing its ownership to approximately 37%. No milestones were completed as at March 31, 2018. As of March 31, 2019, the Milestones have not been achieved, thus the Company has not made any payments for the Stimunity Commitment.

Under the shareholders agreement, Portage has (i) a preferential subscription right to maintain its equity interest in Stimunity in the event of a capital increase from the issuance of new securities by Stimunity, except for issuances of new securities for stock options under a merger plan or for an acquisition, or (ii) the right to vote against any (a) issuances of additional securities that would call for the Company to waive its preferential subscription right or (b) any dilutive issuance.

The following table illustrates the summarized financial information of the Company's investment in Stimunity S.A (in millions):

	March 31, 2019		March 31, 2018
	Unaudited		Unaudited
Current assets	$	1.1	$	0.7
Non-current assets		-		-

Current liabilities		0.3		0.1
Equity		0.9		0.6

Company's share of equity -36.5% and 27.4%	$	0.3	$	0.2

	For the year ended March 31, 2019			For the year ended March 31, 2018
	Unaudited			Unaudited

Revenue	$	0.2		$	-

Income (loss) from operations	$	(0.5	)	$	-

Net loss	$	(0.5	)	$	-

Investment in Pgl

12 Months Ended

Mar. 31, 2019

Investment in Pgl

INVESTMENT IN PGL

8.	INVESTMENT IN PGL

On January 31, 2018, the Company's wholly owned subsidiary, PPL, purchased 650 ordinary shares of Portage Glasgow Ltd. (PGL), a newly incorporated company in Glasgow, Scotland at £0.01 per share for a total consideration of £6.50 ($9.11). PPL's ownership comprised 65% of the issued ordinary shares in PGL. PPL's Chief Executive Officer ("CEO") is also the chairman of the board of directors of PGL which currently consists of two persons. PGL is therefore considered a subsidiary and consolidated.

As per the terms of a Convertible Loan Agreement dated January 31, 2018 signed with PGL, PPL has committed to provide PGL with an unsecured convertible loan facility up to £1 million ($1.4 million) with a minimum drawdown of £50,000 ($70,075) and maximum drawdown of £250,000 ($350,375) during any three-month period. Interest will be at 7% accruing on a monthly basis and the facility is repayable within nine years from the date of the agreement. The outstanding loan with accrued interest can be converted into ordinary shares of PGL to be priced at between £9,000 per share and £5,000 per share depending on the conversion date being within one year to eight years. However, completion of an eligible fundraising by PGL, being £5 million ($7 million) at a pre-money valuation of minimum £10 million ($14 million), will require the loan to be mandatorily converted as per the terms of conversion described above. As at March 31, 2018, there was no drawdown against this facility. The total drawdown during the year ended March 31, 2019 amounted to $45,378.

PPL is also committed to providing a contribution of £33,419 ($46,837) payable in instalments of £11,140 ($15,606) per year for tuition expenses with the University of Glasgow (see note 17). One instalment of $15,606 was made in 2018. The 2019 installment of $15,606 has been accrued but not paid.

Investments in Private Companies

12 Months Ended

Mar. 31, 2019

Investments in Private Companies [Abstract]

INVESTMENTS IN PRIVATE COMPANIES

9.	INVESTMENTS IN PRIVATE COMPANIES

	2019		2018
Year ended March 31,	in 000'$		in 000'$
Sentien Biotechnologies Inc. ("Sentien")		700		700
Intensity		4,500		-
	$	5,200	$	700

Sentien

In August 2015, the Company acquired 210,210 shares of Series A preferred stock in Sentien ("Preferred Stock"), a Medford, MA based private company for $700,000 of cash. The Preferred Stock is fully convertible into equal number of common shares. The Company's holdings represent 5.06% of the equity of Sentien on a fully diluted basis as at March 31, 2019 and 2018, respectively. The investment in Sentien has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through OCI. In accordance with the guidance in IFRS 9 regarding when cost may be the best estimate of fair value, Sentien is recorded at cost (see Note 3).

Intensity

In connection with the SalvaRx Acquisition, the Company acquired a $4.5 million interest in Intensity, a clinical stage biotechnology company, for 1 million shares, or a 7.5% equity interest in Intensity (see Note 10). The investment was recorded at fair value (which approximates cost) at the acquisition date. The investment in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through OCI. The fair value of the asset is determined by considering other comparable equity funding transactions by Intensity with unrelated investors.

Acquisition and Business Combination

12 Months Ended

Mar. 31, 2019

Acquisition and Business Combination [Abstract]

ACQUISITION AND BUSINESS COMBINATION

10.	ACQUISITION AND BUSINESS COMBINATION

On August 13, 2018, the Company reached a definitive agreement to acquire 100% of SalvaRx Limited, a Company incorporated in the British Virgin Islands on May 6, 2015 and formed for the purposes of investing in and acquiring businesses focused on novel cancer immunotherapies and to develop clinical proof of concept, in exchange for 805,070,067 common shares of the Company (the "SalvaRx Acquisition"). The SalvaRx Acquisition was completed on January 8, 2019 (the "Acquisition Date") upon receiving shareholder and regulatory approval. Shares issued by Portage on acquisition were valued at $92.6 million based on the market price of the Company shares of $0.115 per share on the Acquisition Date. Portage is the accounting acquirer as the controlling group of shareholders of Portage increased their holdings, retained majority of voting rights after the acquisition and the Company's management prior to the acquisition continued as management of the combined company. Four of the Company's Board members are also directors of SalvaRx (See Note 19). Notwithstanding the high degree of ownership between the companies, this was not considered a common control transaction as no single individual held controlling interest and no contractual arrangement exists among the group of directors.

In connection with the SalvaRx Acquisition, the Company acquired SalvaRx's five investees and subsidiaries: IOX and Saugatuck (consolidated subsidiary with non-controlling interest), Intensity (investment in private company (see Note 9), Nekonal (joint venture with no fair value due to a dispute with Nekonal, see below), and Rift (no fair value as operations are discontinued). In connection with the SalvaRx Acquisition, the Company also acquired an option from Nekonal SARL that gives SalvaRx the right to acquire shares in Nekonal for €50 ($55 USD) per share for four years. On January 8, 2019, the acquisition date, the fair value of option was determined to be $0 due to a dispute with Nekonal.

SalvaRx and Nekonal are currently involved in a dispute regarding Nekonal's claim that it attained a development milestone that would require SalvaRx to provide the next tranche of funding. SalvaRx claims that Nekonal committed a breach of duties and fraud on its minority shareholders with respect to its assumption that the milestone has been attained. Nekonal management has counterclaimed that SalvaRx in breach of breach of contract with respect to the funding arrangement. While litigation is threatened, no legal proceedings have been formally commenced. Nekonal has halted all development and it intends to so until this matter can be resolved. The Company and Nekonal are currently negotiating a resolution of this matter.

The acquisition of SalvaRx Limited allows the Company to acquire interest in the development of nine immune-oncology products. SalvaRx has three "in-process research and development ("IPR&D") projects identified.

The following table summarizes the purchase price allocation to the fair value of assets acquired and liabilities assumed for SalvaRx:

	In $'000s
Investment in Intensity	$	4,500
Other receivable		641
Cash and cash equivalents		1,192
IPR&D		117,388
Goodwill		43,324
		167,045

Trade and other payables		(625	)
Notes payable		(3,370	)
Convertible notes payable		(100	)
Deferred tax liability, net		(19,673	)
Non-controlling interest (see Note 22) (a)		(48,731	)
		(72,499	)

Fair value of consideration	$	94,546

(a)

Includes the $2.5 million for the fair value of warrants issued with the SalvaRx notes of $2.5 million (see Note 11) and $7.4 million for the fair value of the vested portion of the IOX stock options (see Note 14) that were outstanding at the time of the SalvaRx Acquisition.

The following table summarizes the fair value of consideration in the SalvaRx Acquisition:

	In $'000s

Fair value of common shares of the Company	$	92,583
Effective settlement of intercompany debt (see Note 5 and 12)		1,963
Fair value of consideration	$	94,546

Goodwill has been recognized as a result of SalvaRx's history of discovering and commercializing drugs in the area of cancer immunotherapy and assembled management team. The goodwill acquired is not deductible for tax purposes.

Net losses of $1.9 million from the acquired operations are included in the consolidated statements of operations and other comprehensive income.

Acquisition costs of approximately $0.1 million were incurred and recognized in professional fees in the accompanying consolidated statement of operations and other comprehensive loss for the year ended March 31, 2019.

The following table presents unaudited supplemental pro forma consolidated net income based on SalvaRx's historical reporting periods as if the SalvaRx Acquisition had occurred as of April 1, 2018:

	2019
Year ended March 31,	in 000'$
Net loss	$	(5,160	)
Net loss applicable to common stockholders	$	(3,920	)
Net loss per share, basic and diluted	$	(0.01	)

Accounts Payable and Accrued Liabilities

12 Months Ended

Mar. 31, 2019

Accounts Payable and Accrued Liabilities [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

11.	ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	2019		2018
Year ended March 31,	in 000'$		in 000'$
Accounts payable		388		29
Accrued interest		523		-
Other accrued expenses		196		98
	$	1,107	$	127

Unsecured Notes Payable and Warrants

12 Months Ended

Mar. 31, 2019

Unsecured Notes Payable and Warrants [Abstract]

UNSECURED NOTES PAYABLE AND WARRANTS

12.	UNSECURED NOTES PAYABLE AND WARRANTS

During the year ended March 31, 2017, the Company's subsidiaries, PPL and Eygen, commenced debt financing transactions through a private placement of unsecured notes (the "Unsecured Notes"). The aggregate principal amount of the Unsecured Notes was $250,000 at March 31, 2019 and 2018.

The Unsecured Notes bear interest at 7% per annum, payable annually on the issuance date. The Unsecured Notes are not redeemable by the Company prior to the maturity date of March 2020. In conjunction with the issuance of the Unsecured Notes, the note holders were also issued a warrant to subscribe for $7,500 new PPL or Eygen ordinary shares for every $10,000 of principal issued, respectively, provided that a certain qualifying event occurs within the three years of issuance. The warrants are only exercisable on a qualifying event and the exercise price of the warrant will be based on the price of equity shares determined by the qualifying event and the year in which it takes place. The warrants have a three year term. Given that there was an obligation to issue a variable number of shares, the warrants were classified as financial liabilities and recorded at fair value of $24,000 in warrant liabilities in the accompanying consolidated balance sheet.

The Company did not incur financing costs in connection with this placement of notes.

In connection with the SalvaRx Acquistion in January 2019, the Company assumed $3.96 million of principal in unsecured notes due on March 2, 2021 (or a qualifying event), that bear interest of 7% (the "SalvaRx Notes"). As the SalvaRx Acquisition was a qualifying event, the unsecured notes became due upon the acquisition. On December 23, 2019, the maturity date of $3.0 million SalvaRx Notes was extended to 2021 (see Note 23), accordingly $3.0 million of the SalvaRx Notes are included in current liabilities. On January 8, 2019, the acquisition date, the fair value of the SalvaRx Notes was determined to be $3.4 million (see Note 10) using a 12.5% market interest rate to discount all payments of principal and interest due to the holders of such notes through the date of maturity. The holders of the SalvaRx Notes received $7,500 of warrants in respect of each $10.0 thousand of principal issued. The warrants vest in the event of a qualifying transaction and are exercisable at a 30% discount to the implied valuation of SalvaRx. On the Acquisition Date, the fair value of warrants, which are included in non-controlling interest, was determined to be $2.5 million (see Note 10) using the Black Scholes Model with the following assumptions:

Fair value of stock	$	1,354.88
Risk free interest rate		1	%
Expected dividend		Nil
Expected volatility		80	%
Expected life		2.6 years

In connection with the SalvaRx Acquistion in January 2019, the Company assumed $2.0 million of 7% convertible notes issued by IOX, a wholly-owned subsidiary of SalvaRx (the "Convertible Notes"), of which the Company holds $1.9 million. As a result of the SalvaRx Acquisition, IOX has become a subsidiary of the Company during the year ended March 31, 2019. In accordance with IFRS 3 – Business combinations, the fair value notes payable are effectively settled against the note receivable (see Note 5) upon the business combination and the fair value of the notes receivable is additional consideration (see Note 10). The remaining Convertible Notes issued to third parties, including the conversion option, are recorded at a fair value of $0.1 million (see Note 10) on the Acquisition Date. In each of March 2019 and December 2019, $0.05 million of the Convertible Notes mature. The holders of the Convertible Notes can convert the notes and accrued interest into ordinary shares of IOX at any time before maturity at £120 per share. There is an automatic conversion in the event IOX raises $2 million, and the conversion price will be determined based on the timing of the capital raise and the price at which the money was raised. IOX has right to repay the Convertible Notes together with accrued interest at any time.

Following is a rollforward of the notes payable and the warrant liability:

Notes payable:

	PPL		Eygen		IOX		SalvaRx		Total
	in 000'$		in 000'$		in 000'$		in 000'$		in 000'$
Balance, April 1, 2017	$	181	$	-	$	-	$	-	$	181
Additional issuance		22		23		-		-		45
Interest		7		-		-		-		7
Balance, March 31, 2018	$	210	$	23	$	-	$	-	$	233

	PPL			Eygen			IOX		SalvaRx		Total
	in 000'$			in 000'$			in 000'$		in 000'$		in 000'$
Balance, April 1, 2018	$	210		$	23		$	-	$	-	$	233
Repayment		(25	)		(25	)		-		-		(50	)
Interest		8			2			-		-		10
Fair value on acquisition		-			-			100		3,370		3,470
Balance, March 31, 2019	$	193		$	-		$	100	$	3,370	$	3,663

Warrant liability:

	PPL		Eygen		Total
	in 000'$		in 000'$		in 000'$
Balance, April 1, 2017	$	20	$	-	$	20
Grants		2		2		4
Balance, March 31, 2018	$	22	$	2	$	24

	PPL		Eygen		Total
	in 000'$		in 000'$		in 000'$
Balance, April 1, 2018	$	22	$	2	$	24

Balance, March 31, 2019	$	22	$	2	$	24

Capital Stock

12 Months Ended

Mar. 31, 2019

Capital Stock [Abstract]

CAPITAL STOCK

13.	CAPITAL STOCK

Authorized Common shares: Unlimited number of common shares without par value.

Year ended March 31,	2019				2018
	Common				Common
	Shares		Amount		Shares		Amount
	in 000'		in '000$		in 000'		in '000$
Balance, beginning of year		280,720	$	23,654		260,689	$	18,360
Options exercised (i)		-		-		18,471		4,358
Shares issued as compensation (ii)		-		-		1,560		936
Shares issued on acquisition of SalvaRx Limited (iii)		805,070		92,583		-		-
Balance, end of year		1,085,790	$	116,237		280,720	$	23,654

(i)

During the year ended March 31, 2018, 18,471,026 options were exercised for an equal number of common shares at an average exercise price of $0.15 per share for gross proceeds of $2,725,654. In addition, $1,631,734 being the value of options exercised was transferred from option reserve to capital stock. Options exercised included 13,414,789 options exercised by the directors.

(ii)

During the year ended March 31, 2018, 1,560,000 shares were issued under the Company's 2011 Consultant Stock Compensation Plan to six consultants including 1,390,000 to five directors, for services provided. The shares were valued at $936,000 based on the market price of the Company's common shares prevailing on the date of their issuance.

(iii)

On January 8, 2019, the Company issued 805,070,067 common shares to acquire SalvaRx (see Note 10). The total consideration of $92,583,058 was based on the quoted market price of $0.115 per share on January 8, 2019.

Share-Based Payment

12 Months Ended

Mar. 31, 2019

Share Based Payment [Abstract]

SHARE-BASED PAYMENT

14.	SHARE-BASED PAYMENT

The following table provides the activity for the Company's stock option reserve for the years ended March 31, 2019 and 2018 (in 000's):

	Non-Controlling Interest		Stock Option Reserve
Balance, March 31, 2017	$	-	$	1,706
Stock based compensation expense		-		193
Stock options exercised		-		(1,632	)
Balance, March 31, 2018		-		267
Value of IOX options relating to pre-acquisition services		7,364		-
Stock based compensation expense		1,111		57
Balance, March 31, 2019	$	8,475	$	324

The $7.4 million fair value of vested IOX options acquired in the SalvaRx Acquisition and the stock based compensation expense for unvested options are included in non-controlling interest in the combined balance sheets as of March 31, 2019.

Stock Options

The Board of Directors of the Company (the "Board") established a stock option plan (the "2013 Option Plan") under which options to acquire common shares of the Company are granted to directors, employees and consultants of the Company. The maximum number of common shares issuable under the 2013 Option Plan shall not exceed 10% of the total number of issued and outstanding common shares, inclusive of all shares presently reserved for issuance pursuant to previously granted stock options. If a stock option was surrendered, terminated or expired without being exercised, the common shares reserved for issuance pursuant to such stock option were available for new stock options granted under the 2013 Option Plan. The options vest on a schedule determined by the Board of Directors, generally over two to four years, and expire after five years.

As of March 31, 2019, the Board decided to discontinue the 2013 Option Plan. There are 595,974 stock options issued under this plan. No additional shares will be issued under this plan.

From time to time the Board issues stock options to acquire common shares of PPL, a wholly-owned subsidiary of the Company, are granted to directors, employees and consultants of PPL (the "PPL Option Plan"). On September 17, 2018, the Company issued 9,341 stock options to acquire up to 2% of PPL, with an exercise price of $5.35 per common share, to PPL's CEO. The stock options vest quarterly over 4 years and expire in five years. The fair value of these stock options on the date of grant have been estimated at a fair value of $0.04 million using a Black-Scholes option pricing model with the following assumptions:

Risk free interest rate	1	%
Expected dividend	Nil
Expected volatility	68.86	%
Expected life	1826 days
Fair value of stock	US$6.27

In January 2019, IOX, a subsidiary of SalvaRx, was acquired by the Company as part of the SalvaRx Acquisition. Accordingly, the 2,599 stock options to acquire common shares of IOX (the "Acquired Options") with an exercise price of £120 ($152.84) per common share, outstanding under the IOX stock option plan ("IOX Option Plan") have been acquired by the Company. At the Acquisition Date, 1,643 of the stock options, with a fair value at the Acquisition Date of $7.4 million, are fully vested and recorded in non-controlling interest with a corresponding increase to goodwill (see Note 10). The fair value of the remaining 956 unvested stock options is $4.3 million and will be recorded as compensation expense over the remaining 3-year vesting period. $1.1 million was recorded in compensation expense for the year ended March 31, 2019. The Acquired Options have a 2.6-year weighted average remaining contractual life. Following are the weighted average assumptions used in the calculation of the fair value of the vested and unvested options on the Acquisition Date:

Assumption	Vested Options			Unvested Options
Risk free interest rate		2.6	%		2.6	%
Expected dividend		Nil			Nil
Expected volatility		80	%		80	%
Expected life		1.3 years			3.2 years
Fair value of stock		US$4,630.35			US$4,630.35

There were no other options issued under the IOX Option Plan.

The following is a summary of all outstanding stock options:

	PBI 2013 Option Plan			PPL Option Plan (Subsidiary Plan)		iOx Option Plan (Subsidiary Plan)
Balance at April 1, 2016		16,750,000			47,917		-

Granted		3,566,868			-		-

Balance as at April 1, 2017		20,316,868			47,917		-

Granted		-			-		-

Exercised		(18,471,026	)		-		-

Balance as at March 31, 2018		1,845,842			47,917		-

Acquired from SalvaRx Acquisition		-			-		2,599

Granted		-			9,341		-

Cancelled		(1,250,000	)		-		-

Balance as at March 31, 2019		595,842			57,258		2,599

Exercisable as at March 31, 2019		595,842			50,253		1,728

The weighted average exercise price for the stock options exercised for the year ended March 31, 2018 was $0.15 per share.

Following are the weighted average exercise price and the remaining contractual life for outstanding options by plan:

	PBI				PPL				iOx
March 31,	2019		2018		2019		2018		2019
Weighted average exercise price	$	0.15	$	0.15	$	2.83	$	2.34	$	152.84
Weighted average remaining contractual life (in years)		2.72		3.63		1.63		1.92		3.10

The options can be exercised at any time after vesting within the exercise period in accordance with the applicable option agreement. The exercise price was more than the market price on the date of the grants for all options outstanding as at March 31, 2019 and March 31, 2018.

The Company recorded $1.2 million, $1.1 million and $1.7 million of compensation expense related to the stock option plans for the years ended March 31, 2019, 2018 and 2017, respectively.

Consultant Stock Plan

In March 2011 and March 2017, the Board established the 2011 Consultant Stock Compensation Plan (the "2011 Plan") and the 2017 Stock Compensation Plan (the "2017 Plan"), respectively, under which the Company awards stock to employees, consultants and contractors as compensation.

As at March 31, 2018 and 2017, the Company had the following activity for the Consultant stock Compensation Plans:

	2011 Plan			2017 Plan
Registered		6,000,000			7,250,000
Issued to March 31, 2017		(4,438,333	)		(7,250,000	)
Balance as at April 1, 2017		1,561,667			-
Issued		(1,560,000	)		(7,250,000	)
Cancelled		(1,667	)		-
Balance as at March 31, 2018		-			(7,250,000	)
Balance as at March 31, 2019		-			(7,250,000	)

During the year ended March 31, 2018, 1,560,000 shares were issued under 2011 Consultant Stock Compensation Plan to six consultants including 1,390,000 to five directors, for services provided. The shares fair value of $0.9 million, based on the market price of the Company's common shares prevailing on the date of their issuance, was included in consulting fee expense for the year ended March 31, 2018.

On March 21, 2017, four of the directors were issued 7,250,000 shares under the 2017 Consultants Stock Compensation Plan in lieu of cash fee for services provided. The shares were valued at $1.3 million based on the market price of the Company's common shares on the respective dates of grant. Since the shares were issued without any conditions of forfeiture or cancellation, the entire fair value was expensed during the year ended March 31, 2017 as consulting fee.

Taxation

12 Months Ended

Mar. 31, 2019

Income Tax [Abstract]

TAXATION

15.

TAXATION

The Company is a British Virgin Island corporation. The Government of the British Virgin Islands does not, under existing legislation, impose any income or corporate tax on corporations.

PGL and iOx are subject to United Kingdom taxes ("UK Taxes"). Portage Services Ltd. Is subject to taxes in Canada. Tax losses or potential tax credits for Portage Services Ltd. are insignificant.

iOx has research and development cash credits of approximately $22,000 that have been recorded for year ended March 31, 2019.

As at March 31, 2019, tax losses for IOX were approximately $2.1 million (2018: nil). Tax losses for IOX acquired in the SalvaRx acquisition were $1.5 million and tax losses subsequent to the SalvaRx acquisition were $0.6 million. Tax losses will be carried forward and are potentially available for utilization against taxable profits in future years. The Company has not recognized a deferred tax asset in respect of these tax losses as there is insufficient evidence of suitable future profit being available against which these losses can be offset. The deferred tax asset will be recognized in future periods when its recovery (against appropriate taxable profits) is considered probable.

As at March 31, 2019, iOx had a deferred tax liability of approximately $20.4 million (2018: nil). On January 8, 2019, the Company recognized a $19.8 million deferred tax liability for the difference between the book and income tax basis of IPR&D acquired as part of the acquisition of SalvaRx. As the IPR&D process is in the UK, the deferred tax has been recorded at 17%, the rate applicable in the UK. As the deferred tax liability may be settled in the future in Great British Pounds ("GBP"), the Company increased the deferred tax liability by $0.6 million for the difference in exchange rates from 1.27 USD per GBP on January 8, 2019 to 1.31 USD per GBP on March 31, 2019.

The following is a reconciliation of the UK Taxes to the effective income tax rates for the year ended March 31, 2019:

Statutory UK income tax rate	(17.0	)%
Stock-based compensation	11.4	%
R&D credits	(0.2	)%
Change in Valuation Allowance	5.8	%
Income Taxes Provision (Benefit)	-	%

At March 31, 2019, the Company's deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following ($ in thousands):

Deferred tax assets:
Net-operating loss carryforward at acquisition date	$	252
Net-operating loss carryforward post acquisition		96
Valuation allowance		(348	)
Deferred tax asset, net of allowance	$	-
Deferred tax liabilties:
In-process R&D	$	(20,364	)

Earnings (Loss) Per Share

12 Months Ended

Mar. 31, 2019

Earnings Loss Per Share [Abstract]

EARNINGS (LOSS) PER SHARE

16.	EARNINGS (LOSS) PER SHARE

Basic Earnings Per Share ("EPS") is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the year.

Diluted EPS is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

The following table reflects the income and share data used in the basic and diluted EPS calculations:

	2019			2018		2017
Year ended March 31,	in 000'$			in 000'$		in 000'$
Numerator
Net income(loss) attributable to owners of the Company	$	(2,217	)	$	123,741	$	16,299
Denominator		in 000'			in 000'		in 000'
Weighted average number of shares - Basic		481,987			267,796		254,053
Diluted effect of average number of options		-			1,846		18,150
Weighted average number of shares - Diluted		481,987			269,642		272,193
Basic earnings (loss) per share	$	0.00		$	0.46	$	0.06
Diluted earnings (loss) per share	$	0.00		$	0.46	$	0.06

Inclusion of the Company's 595,842 stock options in the computation of diluted loss per share for the year ended March 31, 2019 would have an anti-dilutive effect on the loss per share and are therefore excluded from the computation. Consequently, there is no difference between loss per share and diluted loss per share for the year ended March 31, 2019.

Commitments and Contingencies

12 Months Ended

Mar. 31, 2019

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

17.

COMMITMENTS AND CONTINGENCIES

(a)

Under the terms of a License Agreement dated January 25, 2013, PPL is required to reimburse to the Licensor, Trojan Technologies Limited ("Trojan"), 50% of all maintenance costs of the US Patent #7,968,512 and to pay royalties of 3% on Net Receipts from sales of the Licensed Product and 5% on Net Receipts from third parties in respect of development or other exploitation of Licensed Intellectual Property and/or Licensed Products up to a maximum of $30 million. As at March 31, 2019, no royalties have been earned and maintenance fees are insignificant, therefore no payments have been made to Trojan.

(b)

The Company is committed to invest approximately €1.5 million ($1.9 million) in Stimunity upon Stimunity's achievement of certain agreed milestones. As at March 31, 2019, the Company has made an additional discretionary investment of €600,129 ($688,359) toward the commitment (see Note 7).

(c)

PPL is committed to provide a loan facility to PGL of up to £1 million ($1.4 million) and studentship grants to the University of Glasgow of £22,279 ($31,224) in equal instalments over the next two years. One instalment of $15,606 was made in 2018. However, no instalments were made in 2019. See Note 8.

(d)

SalvaRx has an obligation to make further capital contribution of €0.3 million ($0.3 million) in Nekonal once certain development milestones have been achieved (see Note 10 and (e) below).

(e)

SalvaRx and Nekonal are currently a in disagreement regarding SalvaRx's obligation to make the additional equity contribution described in (d), which is due upon Nekonal's attainment of the defined milestone. In April 2019, SalvaRx asserted that management of Nekonal committed a breach of duties and fraud on its minority shareholder and Nekonal management has accused SalvaRx of breach of contract stemming from the disagreement as to whether the milestone triggering the requirement to provide funding has been met. To date, no legal proceedings have been formally commenced by either party. Research and development efforts have been suspended pending a resolution of this matter. The Company cannot predict the outcome of this matter and there is no assurance that a loss will not be incurred. (see Notes 10 and 19).

Consulting Fees

12 Months Ended

Mar. 31, 2019

Consulting Fees [Abstract]

CONSULTING FEES

18.

CONSULTING FEES

	2019		2018		2017
Year ended March 31,	in 000'$		in 000'$		in 000'$
Cash fee to management and others	$	476	$	206	$	226
Shares and vested Options issued to key management and directors		755		941		1,572
Shares and vested Options issued to others		390		188		125
	$	1,621	$	1,335	$	1,923

Related Party Transactions

12 Months Ended

Mar. 31, 2019

RELATED PARTY TRANSACTIONS

19.

RELATED PARTY TRANSACTIONS

SalvaRx Acquisition

On January 8,2019 the Company acquired 100% of SalvaRx Limited from SalvaRx Group plc. in exchange for 805,070,067 common shares of the Company for an aggregate consideration of US$92.6 million (see note 10). Four of the six directors of the Company are also directors of SalvaRx Group plc. The Company's CEO is also the CEO of SalvaRx Limited and employees of the Company comprise the management team of SalvaRx Limited.

Investments

The Company has entered into related party transactions and certain services agreement with its joint venture and investments. Key management of the Company has also entered into related party transactions with the joint venture and investments. Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. The Board of Directors, Chairman, Chief Executive Officer and Chief Financial Officer are key management personnel. The related party transactions are as follows:

Nekonal

One of the three directors on the Board of Directors of Nekonal is represented by Portage. Under the terms of the Nekonal Agreement, SalvaRx invested an initial €600,000. €300,000 was invested to further the drug development efforts of Nekonal's technology in cancer immunotherapy. Of the investment €50,000 was paid to each of SalvaRx and Nekonal SARL for fees called for under the services agreements with SalvaRx (management fees) and Nekonal SARL (scientist fees), respectively, for labor fees. The remainder of €200,000 is used for materials in the labs. Additionally, the CEO of the Company is also the CEO of Nekonal and employees of the Company comprise the management team of Nekonal under the service agreement for management services.

Stimunity

One of the three directors on the Board of Directors of Stimunity is represented by Portage (see Note 7).

IOX

Two of the five directors on the Board of Directors of IOX is represented by Portage. Additionally, Portage has an observer on the Board of IOX. The CEO of the Company is also the CEO of IOX and employees of the Company comprise the management team of IOX (see Note 10).

Saugatuck

One of the three directors on the Board of Directors of Saugatuck is represented by Portage. Additionally, the CEO of the Company is also the CEO of Saugatuck and employees of the Company comprise the management team of Saugatuck (see Note 10).

Intensity

One of the four directors on the Board of Directors of Intensity is represented by Portage. Additionally, the CEO of the Company is an officer and employee of Intensity (see Note 9).

PGL

On January 31, 2018, the Company's wholly-owned subsidiary, PPL, acquired 650 ordinary shares, or 65%, of Portage Glasgow Ltd. (PGL), a newly incorporated company in Glasgow, Scotland at less than $0.01 per share for a total consideration of $9.11. PPL's CEO is also the chairman of the two-person board of directors of PGL (see Note 8).

Prepaid expenses and other receivables include amounts due from a joint venture of $73,412 (2018: $nil). The amount is interest free and repayable on demand (see note 7).

Unsecured Notes Payable/Convertible Notes

On March 7, 2018, the Company invested in convertible notes from IOX. On December 3, 2018, the Company invested an additional $950 in IOX (the "Convertible Notes Receivable"). As a result of the SalvaRx Acquisition, IOX has become a subsidiary of the Company during the year ended March 31, 2019. In accordance with IFRS 3 – Business combinations, the fair value notes receivable are effectively settled upon the business combination and the fair value of the notes receivable is additional consideration (see Notes 5, 10 and 12).

The Unsecured Notes and the SalvaRx Notes include notes of the original amount of approximately $3.2 million issued to directors of the Company (see Note 11).

Related party transactions have been listed above, unless they have been disclosed elsewhere in the consolidated financial statements.

Transactions between the parent company and its subsidiaries, which are related parties, have been eliminated on consolidation and are not disclosed in this note.

Financial Instruments and Risk Management

12 Months Ended

Mar. 31, 2019

Financial Instruments and Risk Management [Abstract]

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

20.	FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company's financial instruments recognized in the balance sheet consist of the following:

Fair value estimates are made at a specific point in time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of significant judgment, therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

The following table summarizes the Company's financial instruments as at March 31, 2019:

	Amortized cost		Fair value to other comprehensive income
Financial Assets	In '000s		In '000s
Cash and cash equivalents	$	6,166	$	-
Prepaid expenses and other receivables	$	282	$	-
Investment	$	-	$	103

	Amortized cost		FVTPL
Financial Liabilities	In '000s		In '000s
Accounts payable and accrued liabilities	$	1,107	$	-
Unsecured notes payable	$	3,663	$	-
Warrant liability	$	-	$	2,475

The following table summarizes the Company's financial instruments as at March 31, 2018:

	Amortized cost		Fair value to other comprehensive income
Financial Assets	In '000s		In '000s
Cash and cash equivalents	$	7,520	$	-
Prepaid expenses and other receivables	$	44	$	-
Investment	$	-	$	52

	Amortized cost		Fair value to profit and loss account
Financial Liabilities	In '000s		In '000s
Accounts payable and accrued liabilities	$	127	$	-
Unsecured notes payable	$	233	$	-
Warrant liability	$	-	$	24

A summary of the Company's risk exposures as it relates to financial instruments are reflected below:

Fair value of financial instruments

The Company's financial assets and liabilities are comprised of cash, receivables and investments in equities and private entities, accounts payable, warrant liability and unsecured notes payable.

The Company classifies the fair value of these transactions according to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:

	●	Level 1 – Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the reporting date.

	●	Level 2 – Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting date.

●

Level 3 – Values are based on prices or valuation techniques that are not based on observable market data. Investment is classified as level 3 financial instrument.

Assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy.

Management has assessed that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.

The following methods and assumptions were used to estimate their fair values:

Investment in Biohaven: Fair value was based on quoted market price of $51.47 per share (Level 1).

The investment in Nekonal and the option in Nekonal has been listed at a $0 fair value (see Note 10).

Investment in Sentien: fair value of the asset is determined by considering other comparable equity funding transactions by Sentien with unrelated investors. (Level 3).

Investment in Intensity: The fair value of the asset is determined by considering other comparable equity funding transactions by Intensity with unrelated investors. (Level 3).

Unsecured notes payable and warrant liability: The fair value is estimated using a Black Scholes model (Level 3). See Note 12.

There have been no transfers between levels of the fair value hierarchy for the years ended March 31, 2019 and 2018.

The Company's financial instruments are exposed to certain financial risks: credit risk and liquidity risk.

Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected on the statement of financial position.

Cash– Cash is held with major international financial institutions and therefore the risk of loss is minimal.

Other receivable – The Company is exposed to credit risk attributable to its debtor since a significant portion of this amount represents the amount agreed on a settlement of a claim by PPL (Note 4), payable over the next six years. The debtor has so far been diligent in paying the amounts on the due dates and PPL management will be monitoring the account on a regular basis.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due.

The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without incurring unacceptable losses or risking harm to the Company's reputation. The Company holds sufficient cash to satisfy obligations under accounts payable and accruals.

The Company monitors its liquidity position regularly to assess whether it has the funds necessary to meet its operating needs and needs for investing in new projects. The Company believes that it has sufficient funding to finance the committed drug development work, apart from meeting its operational needs for the foreseeable future.

However, as a biotech company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty in global markets could have an impact on the Company's future ability to access capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available to the Company.

Capital Management

12 Months Ended

Mar. 31, 2019

Capital Management [Abstract]

Capital Management

21.	CAPITAL MANAGEMENT

The Company considers the items included in Equity as capital. The Company had payables and accrued expenses of approximately $ 1.1 million as at March 31, 2019 (approximately $ 0.1 million as at March 31, 2018) and current assets, primarily in cash, of approximately $6.6 million (approximately $7.6 million as at March 31, 2018). The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue new business opportunities and to maintain a flexible capital structure which optimizes the costs of capital at an acceptable risk.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets.

As at March 31, 2019, the shareholders' equity was approximately $146.9 million (approximately $ 9.6 million as at March 31, 2018), $6.2 million ($7.5 million as at March 31, 2018) of it was held in the form of cash.

The Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the Company's approach to capital management during the years ended March 31, 2019 and March 31, 2018.

Non-Controlling Interest

12 Months Ended

Mar. 31, 2019

Non Controlling Interest [Abstract]

NON-CONTROLLING INTEREST

22.

NON-CONTROLLING INTEREST

	PGL			SalvaRx		IOX			Saugatuck			Total
	in 000's$			in 000's$		in 000's$			in 000's$			in 000's$
Balance as of April 1, 2018	$	-		$	-	$	-		$	-		$	-
Acquisition date fair values of non-controlling interests in subsidiaries		-			-		38,826			90			38,916
Fair value:
SalvaRx warrants vested upon acquisition		-			2,451		-			-			2,451
Vested portion of IOX stock options		-			-		7,364			-			7,364
Stock based compensation expense		-			-		1,111			-			1,111
Net loss attributable to non-controlling interest		(31	)		-		(925	)		(3	)		(959	)
Non-controlling interest at March 31, 2019	$	(31	)	$	2,451	$	46,376		$	87		$	48,883

Event After the Balance Sheet Date

12 Months Ended

Mar. 31, 2019

Event After the Balance Sheet Date [Abstract]

EVENT AFTER THE BALANCE SHEET DATE

23.	EVENT AFTER THE BALANCE SHEET DATE

On July 11, 2019, the Company entered into an agreement with Fast Forward Innovations Limited ("Fast Forward") to purchase Intensity Holdings Limited ("IHL"), a wholly-owned subsidiary of Fast Forward. Portage has agreed to pay US $1,298,061 for IHL through the issuance of 12,980,610 common shares. The sole asset of IHL consists of 288,458 shares of the private company, Intensity. This transaction will increase Portage's ownership to 1,288,458 shares of Intensity (approximately 9.7% of the outstanding shares of Intensity) (see Note 9).

On December 23, 2019, the maturity date of $3.0 million SalvaRx Notes was extended to 2021. See Note 12.

Significant Accounting Policies (Policies)

12 Months Ended

Mar. 31, 2019

Significant Accounting Policies [Abstract]

Financial instruments

Financial instruments

i) Financial assets

Classification

Measurement

For purposes of subsequent measurement, financial assets are classified in three categories:

Financial assets at amortized cost (debt instruments)

Financial assets at FVTOCI

Financial assets at FVTPL

Financial assets at amortized cost (debt instruments)

The Company measures financial assets at amortized cost if both of the following conditions are met:

The financial asset is held within a business model with the objective of holding the financial asset in order to collect contractual cash flows and;

The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding

The Company's financial assets classified at amortized cost includes other receivable and convertible note receivable (see Note 5).

Financial assets designated at fair value through OCI (equity instruments)

The Company irrevocably elected to classify its investments in Biohaven Pharmaceuticals Holding Company ltd (Biohaven), Sentien and Intensity as FVTOCI.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss.

ii) Financial liabilities

Warrant liability and note payable

Accordingly, at inception a portion of the proceeds was allocated to the fair value of the warrants and the remainder is recorded as a note payable.

In connection with the acquisition of SalvaRx (see Notes 10 and 12), the Company acquired notes payable and associated warrants which were recorded at fair value on the date of the acquisition.

Impairment of financial assets

Impairment of financial assets

Foreign currencies

Foreign currencies

The effect of exchange rates on our foreign currency-denominated asset and liability balances are recorded as foreign currency transaction losses in the determination of net income (loss).

Cash and cash equivalents

Intangible assets acquired in business combinations

Intangible assets acquired in business combinations

Impairment of indefinite life intangible assets other than goodwill

Impairment of indefinite life intangible assets other than goodwill

Share-based payments

Share-based payments

	●	Expected Volatility. The expected volatility rate used to value stock option grants is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry.

	●	Expected Term. The Company used historical experience.

	●	Risk-free Interest Rate. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of the Company's stock option grants.

●

Expected Dividend Yield. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future.

(Loss) Income per Share

Note 16).

Investment in private companies

Investment in private companies

Investments in associates and joint ventures

Investments in associates and joint ventures

The Company has incurred legal or constructive obligations or made payments on behalf of the associate or joint venture.

Research and Development Expenses

Research and Development Expenses

(i)

Research and development

Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is expensed as incurred.

Research and development expenses include all direct and indirect operating expenses supporting the products in development.

(ii)

Subsequent expenditure

(iii)

Clinical trial expenses

Contingent liability

Contingent liability

Determination of fair value

Income Tax

Income Tax

Business Combinations

Business Combinations

Transaction costs that the Company incurs in connection with a business combination are expensed as incurred.

Goodwill

Goodwill

Adoption of New Standards

Adoption of New Standards

IFRS 9 - Financial Instruments

New standards and interpretations not yet adopted

New standards and interpretations not yet adopted

IFRS 16, Leases

IFRIC 23 Uncertainty over Income Tax Treatment

Prepayment Features with Negative Compensation (Amendments to IFRS 9)

Long-term Interests in Associates and Joint Ventures (Amendments to IAS 28)

Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture

Amendments to IAS 23 Borrowing Costs: Annual Improvements to IFRS 2015 – 2017 Cycle

Amendments to IAS 12 Income Taxes: Annual Improvements to IFRS 2015 – 2017 Cycle

Amendments to IFRS 3: Business Combinations: Annual Improvements to IFRS 2015 – 2017 Cycle

Prepaid Expenses and Other Receivable (Tables)

12 Months Ended

Mar. 31, 2019

Prepaid Expenses and Other Receivable [Abstract]

Schedule of prepaid expenses and other receivable

	2019		2018
Year ended March 31,	in 000'$		in 000'$
Prepaid expenses		19		16
R&D credits		208		-
Other receivables		55		28
	$	282	$	44

Convertible Note Receivable (Table)

12 Months Ended

Mar. 31, 2019

Convertible Note Receivable [Abstract]

Schedule of Convertible Note Receivable

Risk free discount rate	3	%
Risk free interest rate	1	%
Volatility	80	%
Dividend yield	Nil

Investment in Biohaven (Table)

12 Months Ended

Mar. 31, 2019

Investment in Biohaven [Abstract]

Schedule of investment in Biohaven

Balance at March 31, 2017	$	58,913
Realized gain on investment		126,000
Realized gain transferred to income on disposition of shares		(24,515	)
Proceeds from sale of investment		(7,289	)
Property dividend of Biohaven shares		(153,056	)
Balance at March 31, 2018		53
Unrealized gain on investment		50
Balance at March 31, 2019	$	103

Investment in Associate (Tables)

12 Months Ended

Mar. 31, 2019

Investment in Associate [Abstract]

Schedule of investment associate

As at April 1, 2017	$	-
Initial investment		681
Share of losses		-
As at March 31, 2018		681
Additional investment		688
Share of losses		(162	)
As at March 31, 2019	$	1,207

Schedule of details of the Company's associate

Name

Principal Activity

Place of Incorporation and principal place of business

Voting rights held as at March 31, 2019

Voting rights held as at March 31, 2018

Associate:

Stimunity S.A.

Biotechnology

Paris, France

36.5

27.4

Schedule of financial information of the associate investment CompanyTableText Block

	March 31, 2019		March 31, 2018
	Unaudited		Unaudited
Current assets	$	1.1	$	0.7
Non-current assets		-		-

Current liabilities		0.3		0.1
Equity		0.9		0.6

Company's share of equity -36.5% and 27.4%	$	0.3	$	0.2

	For the year ended March 31, 2019			For the year ended March 31, 2018
	Unaudited			Unaudited

Revenue	$	0.2		$	-

Income (loss) from operations	$	(0.5	)	$	-

Net loss	$	(0.5	)	$	-

Investments in Private Companies (Tables)

12 Months Ended

Mar. 31, 2019

Investments in Private Companies [Abstract]

Schedule of investments in private companies

	2019		2018
Year ended March 31,	in 000'$		in 000'$
Sentien Biotechnologies Inc. ("Sentien")		700		700
Intensity		4,500		-
	$	5,200	$	700

Acquisition and Business Combination (Tables)

12 Months Ended

Mar. 31, 2019

Acquisition and Business Combination [Abstract]

Schedule of purchase price allocation to the fair value of assets acquired and liabilities

	In $'000s
Investment in Intensity	$	4,500
Other receivable		641
Cash and cash equivalents		1,192
IPR&D		117,388
Goodwill		43,324
		167,045

Trade and other payables		(625	)
Notes payable		(3,370	)
Convertible notes payable		(100	)
Deferred tax liability, net		(19,673	)
Non-controlling interest (see Note 22) (a)		(48,731	)
		(72,499	)

Fair value of consideration	$	94,546

(a)

Schedule of fair value

	In $'000s

Fair value of common shares of the Company	$	92,583
Effective settlement of intercompany debt (see Note 5 and 12)		1,963
Fair value of consideration	$	94,546

Schedule of pro forma consolidated net income

	2019
Year ended March 31,	in 000'$
Net loss	$	(5,160	)
Net loss applicable to common stockholders	$	(3,920	)
Net loss per share, basic and diluted	$	(0.01	)

Accounts Payable and Accrued Liabilities (Tables)

12 Months Ended

Mar. 31, 2019

Accounts Payable and Accrued Liabilities [Abstract]

Schedule of accounts payable and accrued liabilities

	2019		2018
Year ended March 31,	in 000'$		in 000'$
Accounts payable		388		29
Accrued interest		523		-
Other accrued expenses		196		98
	$	1,107	$	127

Unsecured Notes Payable and Warrants (Tables)

12 Months Ended

Mar. 31, 2019

Investment in Pgl

Schedule of fair value of warrants assumptions

Fair value of stock	$	1,354.88
Risk free interest rate		1	%
Expected dividend		Nil
Expected volatility		80	%
Expected life		2.6 years

Schedule of notes payable

	PPL		Eygen		IOX		SalvaRx		Total
	in 000'$		in 000'$		in 000'$		in 000'$		in 000'$
Balance, April 1, 2017	$	181	$	-	$	-	$	-	$	181
Additional issuance		22		23		-		-		45
Interest		7		-		-		-		7
Balance, March 31, 2018	$	210	$	23	$	-	$	-	$	233

	PPL			Eygen			IOX		SalvaRx		Total
	in 000'$			in 000'$			in 000'$		in 000'$		in 000'$
Balance, April 1, 2018	$	210		$	23		$	-	$	-	$	233
Repayment		(25	)		(25	)		-		-		(50	)
Interest		8			2			-		-		10
Fair value on acquisition		-			-			100		3,370		3,470
Balance, March 31, 2019	$	193		$	-		$	100	$	3,370	$	3,663

Schedule of warrant liability

	PPL		Eygen		Total
	in 000'$		in 000'$		in 000'$
Balance, April 1, 2017	$	20	$	-	$	20
Grants		2		2		4
Balance, March 31, 2018	$	22	$	2	$	24

	PPL		Eygen		Total
	in 000'$		in 000'$		in 000'$
Balance, April 1, 2018	$	22	$	2	$	24

Balance, March 31, 2019	$	22	$	2	$	24

Capital Stock (Tables)

12 Months Ended

Mar. 31, 2019

Capital Stock [Abstract]

Common shares: Unlimited number of common shares without par value

Year ended March 31,	2019				2018
	Common				Common
	Shares		Amount		Shares		Amount
	in 000'		in '000$		in 000'		in '000$
Balance, beginning of year		280,720	$	23,654		260,689	$	18,360
Options exercised (i)		-		-		18,471		4,358
Shares issued as compensation (ii)		-		-		1,560		936
Shares issued on acquisition of SalvaRx Limited (iii)		805,070		92,583		-		-
Balance, end of year		1,085,790	$	116,237		280,720	$	23,654

(i)

(ii)

(iii)

Share-Based Payment (Tables)

12 Months Ended

Mar. 31, 2019

Share Based Payment [Abstract]

Schedule of stock option reserve

	Non-Controlling Interest		Stock Option Reserve
Balance, March 31, 2017	$	-	$	1,706
Stock based compensation expense		-		193
Stock options exercised		-		(1,632	)
Balance, March 31, 2018		-		267
Value of IOX options relating to pre-acquisition services		7,364		-
Stock based compensation expense		1,111		57
Balance, March 31, 2019	$	8,475	$	324

Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model

Risk free interest rate	1	%
Expected dividend	Nil
Expected volatility	68.86	%
Expected life	1826 days
Fair value of stock	US$6.27

Schedule of fair value of the vested and unvested options

Assumption	Vested Options			Unvested Options
Risk free interest rate		2.6	%		2.6	%
Expected dividend		Nil			Nil
Expected volatility		80	%		80	%
Expected life		1.3 years			3.2 years
Fair value of stock		US$4,630.35			US$4,630.35

Schedule of outstanding stock options

	PBI 2013 Option Plan			PPL Option Plan (Subsidiary Plan)		iOx Option Plan (Subsidiary Plan)
Balance at April 1, 2016		16,750,000			47,917		-

Granted		3,566,868			-		-

Balance as at April 1, 2017		20,316,868			47,917		-

Granted		-			-		-

Exercised		(18,471,026	)		-		-

Balance as at March 31, 2018		1,845,842			47,917		-

Acquired from SalvaRx Acquisition		-			-		2,599

Granted		-			9,341		-

Cancelled		(1,250,000	)		-		-

Balance as at March 31, 2019		595,842			57,258		2,599

Exercisable as at March 31, 2019		595,842			50,253		1,728

Schedule of weighted average exercise price and the remaining contractual life

	PBI				PPL				iOx
March 31,	2019		2018		2019		2018		2019
Weighted average exercise price	$	0.15	$	0.15	$	2.83	$	2.34	$	152.84
Weighted average remaining contractual life (in years)		2.72		3.63		1.63		1.92		3.10

Schedule of activity for the consultant stock compensation plans

	2011 Plan			2017 Plan
Registered		6,000,000			7,250,000
Issued to March 31, 2017		(4,438,333	)		(7,250,000	)
Balance as at April 1, 2017		1,561,667			-
Issued		(1,560,000	)		(7,250,000	)
Cancelled		(1,667	)		-
Balance as at March 31, 2018		-			(7,250,000	)
Balance as at March 31, 2019		-			(7,250,000	)

Taxation (Tables)

12 Months Ended

Mar. 31, 2019

Income Tax [Abstract]

Schedule of effective income tax rates

Statutory UK income tax rate	(17.0	)%
Stock-based compensation	11.4	%
R&D credits	(0.2	)%
Change in Valuation Allowance	5.8	%
Income Taxes Provision (Benefit)	-	%

Schedule of deferred tax assets and liabilities

Deferred tax assets:
Net-operating loss carryforward at acquisition date	$	252
Net-operating loss carryforward post acquisition		96
Valuation allowance		(348	)
Deferred tax asset, net of allowance	$	-
Deferred tax liabilties:
In-process R&D	$	(20,364	)

Earnings (Loss) Per Share (Tables)

12 Months Ended

Mar. 31, 2019

Earnings Loss Per Share [Abstract]

Schedule of basic and diluted EPS calculations

	2019			2018		2017
Year ended March 31,	in 000'$			in 000'$		in 000'$
Numerator
Net income(loss) attributable to owners of the Company	$	(2,217	)	$	123,741	$	16,299
Denominator		in 000'			in 000'		in 000'
Weighted average number of shares - Basic		481,987			267,796		254,053
Diluted effect of average number of options		-			1,846		18,150
Weighted average number of shares - Diluted		481,987			269,642		272,193
Basic earnings (loss) per share	$	0.00		$	0.46	$	0.06
Diluted earnings (loss) per share	$	0.00		$	0.46	$	0.06

Consulting Fees (Tables)

12 Months Ended

Mar. 31, 2019

Consulting Fees [Abstract]

Schedule of consulting fees

	2019		2018		2017
Year ended March 31,	in 000'$		in 000'$		in 000'$
Cash fee to management and others	$	476	$	206	$	226
Shares and vested Options issued to key management and directors		755		941		1,572
Shares and vested Options issued to others		390		188		125
	$	1,621	$	1,335	$	1,923

Financial Instruments and Risk Management (Tables)

12 Months Ended

Mar. 31, 2019

Financial Instruments and Risk Management [Abstract]

Schedule of financial instruments

The following table summarizes the Company's financial instruments as at March 31, 2019:

	Amortized cost		Fair value to other comprehensive income
Financial Assets	In '000s		In '000s
Cash and cash equivalents	$	6,166	$	-
Prepaid expenses and other receivables	$	282	$	-
Investment	$	-	$	103

	Amortized cost		FVTPL
Financial Liabilities	In '000s		In '000s
Accounts payable and accrued liabilities	$	1,107	$	-
Unsecured notes payable	$	3,663	$	-
Warrant liability	$	-	$	2,475

The following table summarizes the Company's financial instruments as at March 31, 2018:

	Amortized cost		Fair value to other comprehensive income
Financial Assets	In '000s		In '000s
Cash and cash equivalents	$	7,520	$	-
Prepaid expenses and other receivables	$	44	$	-
Investment	$	-	$	52

	Amortized cost		Fair value to profit and loss account
Financial Liabilities	In '000s		In '000s
Accounts payable and accrued liabilities	$	127	$	-
Unsecured notes payable	$	233	$	-
Warrant liability	$	-	$	24

Non-Controlling Interest (Tables)

12 Months Ended

Mar. 31, 2019

Non Controlling Interest [Abstract]

Schedule of non-controlling interest

	PGL			SalvaRx		IOX			Saugatuck			Total
	in 000's$			in 000's$		in 000's$			in 000's$			in 000's$
Balance as of April 1, 2018	$	-		$	-	$	-		$	-		$	-
Acquisition date fair values of non-controlling interests in subsidiaries		-			-		38,826			90			38,916
Fair value:
SalvaRx warrants vested upon acquisition		-			2,451		-			-			2,451
Vested portion of IOX stock options		-			-		7,364			-			7,364
Stock based compensation expense		-			-		1,111			-			1,111
Net loss attributable to non-controlling interest		(31	)		-		(925	)		(3	)		(959	)
Non-controlling interest at March 31, 2019	$	(31	)	$	2,451	$	46,376		$	87		$	48,883

Nature of Operations (Details) - USD ($)	12 Months Ended
Nature of Operations (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Nature of Operations (Textual)
Cash	$ 6,166,000	$ 7,520,000
Working capital	4,800,000
Accumulated deficit	$ (16,969,000)	$ (14,334,000)
Cash fund, description	The Company’s current cash is sufficient to fund operations for at least the next 12 months because the Company extended the maturity date of $3.4 million of principal and interest on the SalvaRx Notes to 2021 and can defer discretionary research and development and cash compensation by approximately $1.4 million.

Basis of Presentation (Details)		12 Months Ended
Basis of Presentation (Details)	Feb. 10, 2015	Mar. 31, 2019
Statement Line Items [Line Items]
Ownership interest		30.00%
Portage Glasgow Ltd [Member]
Statement Line Items [Line Items]
Ownership interest		65.00%
United Kingdom based immune-oncology [Member]
Statement Line Items [Line Items]
Ownership interest	60.49%
Saugatuck [Member]
Statement Line Items [Line Items]
Ownership interest		70.00%
IOX [Member]
Statement Line Items [Line Items]
Ownership interest		39.51%

Prepaid Expenses and Other Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Prepaid Expenses and Other Receivable [Abstract]
Prepaid expenses	$ 19	$ 16
R&D credits	208
Other receivables	55	28
Prepaid expenses and other receivable	$ 282	$ 44

Prepaid Expenses and Other Receivable (Details Textual) - PPL Settlement [Member] - USD ($)	Mar. 31, 2019	Mar. 31, 2018	Oct. 31, 2016
Statement Line Items [Line Items]
Supplier amount			$ 120,000
Amount receivable	$ 63,750	$ 11,250
Payable installments	11,250
Non-current portion	$ 45,000	$ 56,250

Convertible Note Receivable (Details)	12 Months Ended
Convertible Note Receivable (Details)	Mar. 31, 2019
Convertible Note Receivable [Abstract]
Risk free discount rate	3.00%
Risk free interest rate	1.00%
Volatility	80.00%
Dividend yield

Convertible Note Receivable (Details Textual) - USD ($)			1 Months Ended	12 Months Ended
Convertible Note Receivable (Details Textual) - USD ($)	Dec. 03, 2018	Mar. 07, 2018	Mar. 07, 2018	Mar. 31, 2019
Convertible Note Receivable [Abstract]
Issued convertible notes		$ 950,000	$ 950	$ 2,000,000
Additional investement	$ 950,000
Interest rate	7.00%
Maturity per share				$ 120
Conversion price discounted				25.00%
Fair value				$ 2,000,000

Investment in Biohaven (Details) - USD ($) $ in Thousands	12 Months Ended
Investment in Biohaven (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Investment in Biohaven [Abstract]
Balance at March 31, 2017	$ 52	$ 58,913
Realized gain on investment		126,000
Realized gain transferred to income on disposition of shares		(24,515)
Proceeds from sale of investment		7,289
Property dividend of Biohaven shares		(153,056)
Unrealized gain on investment	50		24,547
Balance at March 31, 2018	$ 103	$ 52	$ 58,913

Investment in Biohaven (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
Investment in Biohaven (Details Textual) - USD ($)	Feb. 02, 2018	Mar. 31, 2019	Mar. 31, 2018	Jan. 31, 2018	Feb. 15, 2017
Statement Line Items [Line Items]
Fair value shares investment		2,000	2,000
Fair value amount		$ 102,940	$ 52,520
Fair value per share		$ 51.47	$ 25.76	$ 0.01
Unrealized gains		$ 50,420
Biohaven [Member]
Statement Line Items [Line Items]
Held in shares					6,341,500
Sale of shares	236,770
Market average price	$ 30.79
Proceeds shares amount	$ 7,300,000

Investment in Associate (Details) - USD ($) $ in Thousands	12 Months Ended
Investment in Associate (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Investment in Pgl
Balance	$ 681
Initial investment		681
Additional investment	688
Share of losses	(162)
Balance	$ 1,207	$ 681

Investment in Associate (Details 1) - Stimunity S.A. [Member]	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement Line Items [Line Items]
Name	Stimunity S.A.
Principal Activity	Biotechnology
Place of Incorporation and principal place of business	Paris, France
Voting rights held	36.50%	27.40%

Investment in Associate (Details 2) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Statement Line Items [Line Items]
Current assets	$ 6,551	$ 7,616
Current liabilities	1,794	151
Equity	148,557	9,619	$ 59,594	$ 12,329
Company's share of equity -36.5% and 27.4%	99,674	9,619
Stimunity S.A. [Member]
Statement Line Items [Line Items]
Current assets	700	1,100
Non-current assets
Current liabilities	100	300
Equity	600	900
Company's share of equity -36.5% and 27.4%	$ 200	$ 300

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

Investment in Associate (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Statement Line Items [Line Items]
Income (loss) from operations	$ (2,764)	$ (2,235)	$ (35,499)
Net loss	(3,594)	123,741	$ (641)
Stimunity S.A. [Member]
Statement Line Items [Line Items]
Revenue	200
Income (loss) from operations	(500)
Net loss	$ (500)

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2019-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2019-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2019-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2019-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2019-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2019-03-27

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2019-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2019-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2019-03-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23&doctype=Standard
-URIDate 2019-03-27

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2019-03-27

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2019-03-27

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2019-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2019-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2019-03-27

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2019-03-27

+ Details

- Definition

Expiry date 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants. Effective 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_32&doctype=Standard
-URIDate 2019-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2019-03-27

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_34&doctype=Standard
-URIDate 2019-03-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2019-03-27

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_103&doctype=Standard
-URIDate 2019-03-27

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_102&doctype=Standard
-URIDate 2019-03-27

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2019-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2019-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2019-03-27

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2019-03-27

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2019-03-27

+ Details

Investment in Associate (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Mar. 25, 2019	Feb. 28, 2018	Mar. 31, 2019	Mar. 31, 2018
Statement Line Items [Line Items]
Initial investment				$ 681
Additional investments			$ 688
Stimunity S.A. [Member]
Statement Line Items [Line Items]
Initial investment		$ 700
Subscribing class A shares		3,780
Second investments		$ 1,900
Additional investments	$ 700
Subscribing ordinary shares	1,945	4,140
Ownership equity interest	37.00%	27.00%
Stimunity S.A. [Member] \| EURO
Statement Line Items [Line Items]
Initial investment		$ 500
Second investments		$ 1,500
Additional investments	$ 600
Shares price	$ 308.55	$ 363

Investment in Pgl (Details) - $ / shares	1 Months Ended	12 Months Ended
Investment in Pgl (Details) - $ / shares	Jan. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Investment in Pgl (Textual)
Shares purchased or subscribed	650
Price per share	$ 0.01	$ 51.47	$ 25.76
Business combination, description	The Company's wholly owned subsidiary, PPL, purchased 650 ordinary shares of Portage Glasgow Ltd. (PGL), a newly incorporated company in Glasgow, Scotland at £0.01 per share for a total consideration of £6.50 ($9.11).	PPL is also committed to providing a contribution of £33,419 ($46,837) payable in instalments of £11,140 ($15,606) per year for tuition expenses with the University of Glasgow (see note 17). One instalment of $15,606 was made in 2018. The 2019 installment of $15,606 has been accrued but not paid.
Percentage of equity held	65.00%
Convertible loan agreement, description	PPL has committed to provide PGL with an unsecured convertible loan facility up to £1 million ($1.4 million) with a minimum drawdown of £50,000 ($70,075) and maximum drawdown of £250,000 ($350,375) during any three-month period. Interest will be at 7% accruing on a monthly basis and the facility is repayable within nine years from the date of the agreement. The outstanding loan with accrued interest can be converted into ordinary shares of PGL to be priced at between £9,000 per share and £5,000 per share depending on the conversion date being within one year to eight years. However, completion of an eligible fundraising by PGL, being £5 million ($7 million) at a pre-money valuation of minimum £10 million ($14 million), will require the loan to be mandatorily converted as per the terms of conversion described above. As at March 31, 2018, there was no drawdown against this facility. The total drawdown during the year ended March 31, 2019 amounted to $45,378.

Investments in Private Companies (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Statement Line Items [Line Items]
Investments	$ 5,200	$ 700
Sentien Biotechnologies Inc. [Member]
Statement Line Items [Line Items]
Investments	700	700
Intensity [Member]
Statement Line Items [Line Items]
Investments	$ 4,500

Investments in Private Companies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Investments in Private Companies (Textual)
Investment	$ 5,200	$ 700
Series A preferred stock in Sentien Biotechnologies [Member]
Investments in Private Companies (Textual)
Investment	$ 700,000	$ 700,000
Percentage of equity held	5.06%	5.06%
Number of shares purchased	210,210	210,210
Intensity [Member]
Investments in Private Companies (Textual)
Investment	$ 4,500
Percentage of equity held	7.50%
Number of shares purchased	1,000

Acquisition and Business Combination (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Aug. 13, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Statement Line Items [Line Items]
Investment in Intensity	$ 5,200		$ 700
Other receivable	282		44
Cash and cash equivalents	6,166		7,520	$ 159	$ 4,689
IPR&D	117,388
Goodwill	43,324
Total assets	173,715		10,003
Trade and other payables	1,107		127
Deferred tax liability, net	(20,364)
Total liabilities	$ 25,158		$ 384
SalvaRx [Member]
Statement Line Items [Line Items]
Investment in Intensity		$ 4,500
Other receivable		641
Cash and cash equivalents		1,192
IPR&D		117,388
Goodwill		43,324
Total assets		167,045
Trade and other payables		(625)
Notes payable		(3,370)
Convertible notes payable		(100)
Deferred tax liability, net		(19,673)
Non-controlling interest		(48,731)
Total liabilities		(72,499)
Fair value of consideration		$ 94,546

Acquisition and Business Combination (Details 1) - SalvaRx [Member] $ in Thousands	Aug. 13, 2018 USD ($)
Statement Line Items [Line Items]
Fair value of common shares of the Company	$ 92,583
Effective settlement of intercompany debt	1,963
Fair value of consideration	$ 94,546

Acquisition and Business Combination (Details 2) - SalvaRx [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2019 USD ($) $ / shares
Statement Line Items [Line Items]
Net loss	$ (5,160)
Net loss applicable to common stockholders	$ (3,920)
Net loss per share, basic and diluted \| $ / shares	$ (0.01)

Acquisition and Business Combination (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Aug. 13, 2018	Jan. 08, 2019	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Jan. 31, 2018
Acquisition and Business Combination (Textual)
Market price of per share			$ 51.47	$ 25.76		$ 0.01
Net losses			$ (3,594)	$ 123,741	$ (641)
Acquisition costs			100
Fair value of warrants			2,500
Fair value of the vested portion			7,400
SalvaRx [Member]
Acquisition and Business Combination (Textual)
Business combination acquisition percentage	100.00%
Exchange of common stock	805,070,067
Cash consideration from issuance of shares		$ 92,600
Market price of per share		$ 0.115
Acquisition of shares, description	In connection with the SalvaRx Acquisition, the Company acquired SalvaRx's five investees and subsidiaries: IOX and Saugatuck (consolidated subsidiary with non-controlling interest), Intensity (investment in private company (see Note 9), Nekonal (joint venture with no fair value due to a dispute with Nekonal, see below), and Rift (no fair value as operations are discontinued). In connection with the SalvaRx Acquisition, the Company also acquired an option from Nekonal SARL that gives SalvaRx the right to acquire shares in Nekonal for €50 ($55 USD) per share for four years. On January 8, 2019, the acquisition date, the fair value of option was determined to be $0 due to a dispute with Nekonal.
SalvaRx Group Plc [Member]
Acquisition and Business Combination (Textual)
Business combination acquisition percentage		100.00%
Exchange of common stock		805,070,067
Fair value of warrants			$ 2,500

Accounts Payable and Accrued Liabilities (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Year ended March 31,
Accounts payable	$ 388	$ 29
Accrued interest	523
Other accrued expenses	196	98
Total	$ 1,107	$ 127

Unsecured Notes Payable and Warrants (Details)	12 Months Ended
Unsecured Notes Payable and Warrants (Details)	Mar. 31, 2019 USD ($)
Unsecured Notes Payable and Warrants [Abstract]
Fair value of stock	$ 1,355
Risk free interest rate	1.00%
Expected dividend
Expected volatility	80.00%
Expected life	2 years 7 months 6 days

Unsecured Notes Payable and Warrants (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement Line Items [Line Items]
Balance	$ 233	$ 181
Additional issuance		45
Repayment	(50)
Interest	10	7
Fair value on acquisition	3,470
Balance	3,663	233
PPL [Member]
Statement Line Items [Line Items]
Balance	210	181
Additional issuance		22
Repayment	(25)
Interest	8	7
Fair value on acquisition
Balance	193	210
Eygen [Member]
Statement Line Items [Line Items]
Balance	23
Additional issuance		23
Repayment	(25)
Interest	2
Fair value on acquisition
Balance		23
IOX [Member]
Statement Line Items [Line Items]
Balance
Additional issuance
Repayment
Interest
Fair value on acquisition	100
Balance	100
SalvaRx [Member]
Statement Line Items [Line Items]
Balance
Additional issuance
Repayment
Interest
Fair value on acquisition	3,370
Balance	$ 3,370

Unsecured Notes Payable and Warrants (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement Line Items [Line Items]
Balance	$ 24	$ 20
Grants		4
Balance	24	24
PPL [Member]
Statement Line Items [Line Items]
Balance	22	20
Grants		2
Balance	22	22
Eygen [Member]
Statement Line Items [Line Items]
Balance	2
Grants		2
Balance	$ 2	$ 2

Unsecured Notes Payable and Warrants (Details Textual) - USD ($)			1 Months Ended			12 Months Ended
	Jan. 08, 2019	Mar. 07, 2018	Dec. 23, 2019	Jan. 31, 2019	Mar. 07, 2018	Mar. 31, 2019	Dec. 31, 2019	Mar. 31, 2018
Unsecured Notes Payable and Warrants (Textual)
Aggregate principal amount of Unsecured Notes						$ 250,000		$ 250,000
Unsecured Notes interest						7.00%
Unsecured Notes maturity date						March 2020
Issuance of unsecured notes, description						In conjunction with the issuance of the Unsecured Notes, the note holders were also issued a warrant to subscribe for $7,500 new PPL or Eygen ordinary shares for every $10,000 of principal issued, respectively, provided that a certain qualifying event occurs within the three years of issuance.
Fair value of warrant liabilities						$ 24,000
Convertible Notes mature						50,000
Conversion amount		$ 950,000			$ 950	$ 2,000,000
SalvaRx [Member]
Unsecured Notes Payable and Warrants (Textual)
Fair value of warrant liabilities				$ 2,500,000
Acquistion, description	The acquisition date, the fair value of the SalvaRx Notes was determined to be $3.4 million (see Note 10) using a 12.5% market interest rate to discount all payments of principal and interest due to the holders of such notes through the date of maturity. The holders of the SalvaRx Notes received $7,500 of warrants in respect of each $10.0 thousand of principal issued. The warrants vest in the event of a qualifying transaction and are exercisable at a 30% discount to the implied valuation of SalvaRx.			The Company assumed $3.96 million of principal in unsecured notes due on March 2, 2021 (or a qualifying event), that bear interest of 7% (the "SalvaRx Notes").
IOX [Member]
Unsecured Notes Payable and Warrants (Textual)
Fair value of warrant liabilities				$ 100,000
Acquistion, description				The Company assumed $2.0 million of 7% convertible notes issued by IOX, a wholly-owned subsidiary of SalvaRx (the "Convertible Notes"), of which the Company holds $1.9 million.
Convertible Notes, per share				$ 120
Conversion amount				$ 2,000,000
Acquisition [Member]
Unsecured Notes Payable and Warrants (Textual)
Convertible Notes mature							$ 50,000
Acquisition [Member] \| SalvaRx [Member]
Unsecured Notes Payable and Warrants (Textual)
Acquistion, description			The maturity date of $3.0 million SalvaRx Notes was extended to 2021 (see Note 23), accordingly $3.0 million of the SalvaRx Notes are included in current liabilities.

Capital Stock (Details) - USD ($)
shares in Thousands, $ in Thousands

12 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Capital Stock [Abstract]

Balance

$ 23,654

$ 18,360

Balance, Shares

280,720

260,689

Options exercised

^[1]

$ 4,358

Options exercised, Shares

^[1]

18,471

Shares issued as compensation

^[2]

$ 936

Shares issued as compensation, Shares

^[2]

1,560

Shares issued on acquisition of SalvaRx Limited

^[3]

$ 92,583

Shares issued on acquisition of SalvaRx Limited, Shares

^[3]

805,070

Balance

$ 116,237

$ 23,654

Balance, Shares

1,085,790

280,720

[1]	During the year ended March 31, 2018, 18,471,026 options were exercised for an equal number of common shares at an average exercise price of $0.15 per share for gross proceeds of $2,725,654. In addition, $1,631,734 being the value of options exercised was transferred from option reserve to capital stock. Options exercised included 13,414,789 options exercised by the directors.
[2]	During the year ended March 31, 2018, 1,560,000 shares were issued under the Company's 2011 Consultant Stock Compensation Plan to six consultants including 1,390,000 to five directors, for services provided. The shares were valued at $936,000 based on the market price of the Company's common shares prevailing on the date of their issuance.
[3]	On January 8, 2019, the Company issued 805,070,067 common shares to acquire SalvaRx (see Note 10). The total consideration of $92,583,058 was based on the quoted market price of $0.115 per share on January 8, 2019.

Capital Stock (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
Capital Stock (Details Textual) - USD ($)	Jan. 08, 2019	Mar. 31, 2018
Captial Stock (Textual)
Options exercised, Common shares		18,471,026
Options exercised, Common per share		$ 0.15
Options exercised, gross proceeds		$ 2,725,654
Option reserve, Capital stock		1,631,734
Company 2011 Consultant Stock Compensation Plan [Member]
Captial Stock (Textual)
Options exercised, Common shares		1,560,000
Market price, Common shares		936,000
Director [Member]
Captial Stock (Textual)
Options exercised, Common shares		13,414,789
Director [Member] \| Company 2011 Consultant Stock Compensation Plan [Member]
Captial Stock (Textual)
Options exercised, Common shares		1,390,000
SalvaRx [Member]
Captial Stock (Textual)
Options exercised, Common shares	805,070,067
Market price, Common shares	92,583,058
Market price, Common per share	$ 0.115

Share-Based Payment (Details) - USD ($) $ in Thousands	12 Months Ended
Share-Based Payment (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Statement Line Items [Line Items]
Stock based compensation expense	$ 1,148	$ 1,129	$ 1,697
Stock options exercised		2,726
Non-Controlling Interest [Member]
Statement Line Items [Line Items]
Balance
Value of IOX options relating to pre-acquisition services	7,364
Stock based compensation expense	1,111
Stock options exercised
Balance	8,475
Stock Option Reserve [Member]
Statement Line Items [Line Items]
Balance	267	1,706
Value of IOX options relating to pre-acquisition services
Stock based compensation expense	57	193	404
Stock options exercised		(1,632)
Balance	$ 324	$ 267	$ 1,706

Share-Based Payment (Details 1) - $ / shares	3 Months Ended	12 Months Ended
Share-Based Payment (Details 1) - $ / shares	Mar. 31, 2019	Mar. 31, 2019
Statement Line Items [Line Items]
Risk free interest rate		1.00%
Expected dividend
Expected volatility		80.00%
Black-Scholes Option Pricing Model [member]
Statement Line Items [Line Items]
Risk free interest rate	1.00%
Expected dividend
Expected volatility	68.86%
Expected life	5 years 32 months 26 days
Fair value of stock	$ 6.27

Share-Based Payment (Details 2)	12 Months Ended
Share-Based Payment (Details 2)	Mar. 31, 2019 $ / shares
Statement Line Items [Line Items]
Risk free interest rate	1.00%
Expected dividend
Expected volatility	80.00%
Vested Options [Member]
Statement Line Items [Line Items]
Risk free interest rate	2.60%
Expected dividend
Expected volatility	80.00%
Expected life	1 year 3 months 19 days
Fair value of stock	$ 4,630.35
Unvested Options [Member]
Statement Line Items [Line Items]
Risk free interest rate	2.60%
Expected dividend
Expected volatility	80.00%
Expected life	3 years 2 months 12 days
Fair value of stock	$ 4,630.35

Share-Based Payment (Details 3) - USD ($) $ in Thousands	12 Months Ended
Share-Based Payment (Details 3) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
PBI 2013 Option Plan [Member]
Statement Line Items [Line Items]
Balance	1,845,842	20,316,868	16,750,000
Acquired from SalvaRx Acquisition
Granted			3,566,868
Exercised		(18,471,026)
Cancelled	(1,250,000)
Balance	595,842	1,845,842	20,316,868
Exercisable as at March 31, 2019	$ 595,842
PPL Option Plan (Subsidiary Plan) [Member]
Statement Line Items [Line Items]
Balance	47,917	47,917	47,917
Acquired from SalvaRx Acquisition
Granted	9,341
Exercised
Cancelled
Balance	57,258	47,917	47,917
Exercisable as at March 31, 2019	$ 50,253
iOx Option Plan (Subsidiary Plan) [Member]
Statement Line Items [Line Items]
Balance
Acquired from SalvaRx Acquisition	$ 2,599
Granted
Cancelled
Balance	2,599
Exercisable as at March 31, 2019	$ 1,728

Share-Based Payment (Details 4) - $ / shares	12 Months Ended
Share-Based Payment (Details 4) - $ / shares	Mar. 31, 2019	Mar. 31, 2018
PBI [Member]
Statement Line Items [Line Items]
Weighted average exercise price	$ 0.15	$ 0.15
Weighted average remaining contractual life (in years)	2 years 8 months 19 days	3 years 7 months 17 days
PPL [Member]
Statement Line Items [Line Items]
Weighted average exercise price	$ 2.83	$ 2.34
Weighted average remaining contractual life (in years)	1 year 7 months 17 days	1 year 11 months 1 day
iOx [Member]
Statement Line Items [Line Items]
Weighted average exercise price	$ 152.84
Weighted average remaining contractual life (in years)	3 years 1 month 6 days

Share-Based Payment (Details 5) - shares	12 Months Ended
Share-Based Payment (Details 5) - shares	Mar. 31, 2018	Mar. 31, 2017
2011 Plan [Member]
Statement Line Items [Line Items]
Registered		6,000,000
Issued	(1,560,000)	(4,438,333)
Balance		1,561,667
Cancelled	(1,667)
Balance
2017 Plan [Member]
Statement Line Items [Line Items]
Registered		7,250,000
Issued	(7,250,000)	(7,250,000)
Balance
Cancelled
Balance	(7,250,000)

Share-Based Payment (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Sep. 17, 2018	Mar. 21, 2017
Share-Based Payment (Textual)
Fair value of vested IOX options acquired		$ 7,400
Stock options issued		595,974
Exercise price			$ 0.15
Stock options vest, description		The stock options vest quarterly over 4 years and expire in five years.
Fair value		$ 40	$ 90	$ 1,300
Compensation expense		$ 1,200	$ 1,100	$ 1,700
Consultant Stock Compensation Plan [Member]
Share-Based Payment (Textual)
Option issued			1,560,000			7,250,000
Shares issued description		Were issued under 2011 Consultant Stock Compensation Plan to six consultants including 1,390,000 to five directors, for services provided.
PPL Option Plan [Member]
Share-Based Payment (Textual)
Option issued					9,341
Exercise price					$ 5.35
SalvaRx [Member]
Share-Based Payment (Textual)
Acquisition, description	Accordingly, the 2,599 stock options to acquire common shares of IOX (the “Acquired Options”) with an exercise price of £120 ($152.84) per common share, outstanding under the IOX stock option plan (“IOX Option Plan”) have been acquired by the Company. At the Acquisition Date, 1,643 of the stock options, with a fair value at the Acquisition Date of $7.4 million, are fully vested and recorded in non-controlling interest with a corresponding increase to goodwill (see Note 10). The fair value of the remaining 956 unvested stock options is $4.3 million and will be recorded as compensation expense over the remaining 3-year vesting period. $1.1 million was recorded in compensation expense for the year ended March 31, 2019. The Acquired Options have a 2.6-year weighted average remaining contractual life.

Taxation (Details)	12 Months Ended
Taxation (Details)	Mar. 31, 2019
Income Tax [Abstract]
Statutory UK income tax rate	(17.00%)
Stock-based compensation	11.40%
R&D credits	(0.20%)
Change in Valuation Allowance	5.80%
Income Taxes Provision (Benefit)	0.00%

Taxation (Details 1)	Mar. 31, 2019 USD ($)
Deferred tax assets:
Net-operating loss carryforward at acquisition date	$ 252
Net-operating loss carryforward post acquisition	96
Valuation allowance	(348)
Deferred tax asset, net of allowance
Deferred tax liabilties:
In-process R&D	$ (20,364)

Taxation (Details Textual)	12 Months Ended
Taxation (Details Textual)	Mar. 31, 2019 USD ($)
Taxation (Textual)
Research and development cash credits	$ 22,000
Tax losses, description	Tax losses for IOX were approximately $2.1 million (2018: nil). Tax losses for IOX acquired in the SalvaRx acquisition were $1.5 million and tax losses subsequent to the SalvaRx acquisition were $0.6 million.
Deferred tax liability, description	IOX had a deferred tax liability of approximately $20.4 million (2018: nil). On January 8, 2019, the Company recognized a $19.8 million deferred tax liability for the difference between the book and income tax basis of IPR&D acquired as part of the acquisition of SalvaRx. As the IPR&D process is in the UK, the deferred tax has been recorded at 17%, the rate applicable in the UK. As the deferred tax liability may be settled in the future in Great British Pounds ("GBP"), the Company increased the deferred tax liability by $0.6 million for the difference in exchange rates from 1.27 USD per GBP on January 8, 2019 to 1.31 USD per GBP on March 31, 2019.

Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Numerator
Net income(loss) attributable to owners of the Company	$ (2,217)	$ 123,741	$ 16,299
Denominator
Weighted average number of shares - Basic	481,987	267,796	254,053
Diluted effect of average number of options		1,846	18,150
Weighted average number of shares - Diluted	481,987	269,642	272,193
Basic earnings (loss) per share	$ (0.00)	$ 0.46	$ 0.06
Diluted earnings (loss) per share	$ 0.00	$ 0.46	$ 0.06

Earnings (Loss) Per Share (Details Textual)	12 Months Ended
Earnings (Loss) Per Share (Details Textual)	Mar. 31, 2019 shares
Earnings (Loss) Per Share (Textual)
Stock options in computation of diluted loss per	595,842

Commitments and Contingencies (Details)	12 Months Ended
Commitments and Contingencies (Details)	Mar. 31, 2019
Commitments and Contingencies (Textual)
Commitments and contingencies, description	(a) Under the terms of a License Agreement dated January 25, 2013, PPL is required to reimburse to the Licensor, Trojan Technologies Limited ("Trojan"), 50% of all maintenance costs of the US Patent #7,968,512 and to pay royalties of 3% on Net Receipts from sales of the Licensed Product and 5% on Net Receipts from third parties in respect of development or other exploitation of Licensed Intellectual Property and/or Licensed Products up to a maximum of $30 million. As at March 31, 2019, no royalties have been earned and maintenance fees are insignificant, therefore no payments have been made to Trojan. (b) The Company is committed to invest approximately ?1.5 million ($1.9 million) in Stimunity upon Stimunity's achievement of certain agreed milestones. As at March 31, 2019, the Company has made an additional discretionary investment of ?600,129 ($688,359) toward the commitment (see Note 7). (c) PPL is committed to provide a loan facility to PGL of up to £1 million ($1.4 million) and studentship grants to the University of Glasgow of £22,279 ($31,224) in equal instalments over the next two years. One instalment of $15,606 was made in 2018. However, no instalments were made in 2019. See Note 8. (d) SalvaRx has an obligation to make further capital contribution of €0.3 million ($0.3 million) in Nekonal once certain development milestones have been achieved (see Note 10 and (e) below). (e) SalvaRx and Nekonal are currently a in disagreement regarding SalvaRx's obligation to make the additional equity contribution described in (d), which is due upon Nekonal's attainment of the defined milestone. In April 2019, SalvaRx asserted that management of Nekonal committed a breach of duties and fraud on its minority shareholder and Nekonal management has accused SalvaRx of breach of contract stemming from the disagreement as to whether the milestone triggering the requirement to provide funding has been met. To date, no legal proceedings have been formally commenced by either party. Research and development efforts have been suspended pending a resolution of this matter. The Company cannot predict the outcome of this matter and there is no assurance that a loss will not be incurred. (see Notes 10 and 19).

Consulting Fees (Details) - USD ($) $ in Thousands	12 Months Ended
Consulting Fees (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Statement Line Items [Line Items]
Consulting fees	$ 1,621	$ 1,335	$ 1,923
Cash fee to management and others [Member]
Statement Line Items [Line Items]
Consulting fees	476	206	226
Shares and vested Options issued to key management and directors [Member]
Statement Line Items [Line Items]
Consulting fees	755	941	1,572
Shares and vested Options issued to others [Member]
Statement Line Items [Line Items]
Consulting fees	$ 390	$ 188	$ 125

Related Party Transactions (Details) - USD ($)		1 Months Ended			12 Months Ended
Related Party Transactions (Details) - USD ($)	Mar. 07, 2018	Jan. 08, 2019	Mar. 07, 2018	Jan. 31, 2018	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018
Related Party Transactions (Textual)
Unsecured Notes original amount	$ 950,000		$ 950			$ 2,000,000
Nekonal Agreement [Member]
Related Party Transactions (Textual)
Investment agreement, description					One of the three directors on the Board of Directors of Nekonal is represented by Portage. Under the terms of the Nekonal Agreement, SalvaRx invested an initial €600,000. €300,000 was invested to further the drug development efforts of Nekonal’s technology in cancer immunotherapy. Of the investment €50,000 was paid to each of SalvaRx and Nekonal SARL for fees called for under the services agreements with SalvaRx (management fees) and Nekonal SARL (scientist fees), respectively, for labor fees. The remainder of €200,000 is used for materials in the labs. Additionally, the CEO of the Company is also the CEO of Nekonal and employees of the Company comprise the management team of Nekonal under the service agreement for management services.
SalvaRx Group plc. [Member]
Related Party Transactions (Textual)
Business combination acquisition percentage		100.00%
Exchange of common stock		805,070,067
Cash consideration from issuance of shares		$ 92,600,000
Portage Glasgow Ltd. [Member]
Related Party Transactions (Textual)
Wholly-owned subsidiary, description				The Company’s wholly-owned subsidiary, PPL, acquired 650 ordinary shares, or 65%, of Portage Glasgow Ltd. (PGL), a newly incorporated company in Glasgow, Scotland at less than $0.01 per share for a total consideration of $9.11.
Prepaid expenses					$ 73,412	$ 73,412

Financial Instruments and Risk Management (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Financial Assets
Cash and cash equivalents	$ 6,166	$ 7,520	$ 159	$ 4,689
Financial Liabilities
Unsecured notes payable	663
Amortized cost [Member]
Financial Assets
Cash and cash equivalents	6,166	7,520
Prepaid expenses and other receivables	282	44
Investment
Financial Liabilities
Accounts payable and accrued liabilities	1,107	127
Unsecured notes payable	3,663	233
Warrant liability
Fair value to other comprehensive income [Member]
Financial Assets
Cash and cash equivalents
Prepaid expenses and other receivables
Investment		52
Fair value to profit and loss account [Member]
Financial Liabilities
Accounts payable and accrued liabilities
Unsecured notes payable
Warrant liability	$ 2,475	$ 24

Financial Instruments and Risk Management (Details Textual)	12 Months Ended
	Mar. 31, 2019 USD ($) $ / shares
Financial Instruments and Risk Management (Textual)
Fair value market price per share \| $ / shares	$ 51.47
Fair value investment and option \| $	$ 0

Capital Management (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Captial Management (Textual)
Payables and accrued expenses	$ 1,100	$ 100
Cash	6,166,000	7,520,000	$ 159,000	$ 4,689,000
Shareholders' equity	148,557,000	9,619,000	$ 59,594,000	$ 12,329,000
Shareholders' equity form of cash.	$ 6,200	$ 7,500

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

Non-Controlling Interest (Details) $ in Thousands	12 Months Ended
Non-Controlling Interest (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Statement Line Items [Line Items]
Balance
Acquisition date fair values of non-controlling interests in subsidiaries	38,916
Fair value:
SalvaRx warrants vested upon acquisition	2,451
Vested portion of IOX stock options	7,364
Stock based compensation expense	1,111
Net loss attributable to non-controlling interest	(959)
Non-controlling interest	48,883
PGL [Member]
Statement Line Items [Line Items]
Balance
Acquisition date fair values of non-controlling interests in subsidiaries
Fair value:
SalvaRx warrants vested upon acquisition
Vested portion of IOX stock options
Stock based compensation expense
Net loss attributable to non-controlling interest	(31)
Non-controlling interest	(31)
SalvaRx [Member]
Statement Line Items [Line Items]
Balance
Acquisition date fair values of non-controlling interests in subsidiaries
Fair value:
SalvaRx warrants vested upon acquisition	2,451
Vested portion of IOX stock options
Stock based compensation expense
Net loss attributable to non-controlling interest
Non-controlling interest	2,451
IOX [Member]
Statement Line Items [Line Items]
Balance
Acquisition date fair values of non-controlling interests in subsidiaries	38,826
Fair value:
SalvaRx warrants vested upon acquisition
Vested portion of IOX stock options	7,364
Stock based compensation expense	1,111
Net loss attributable to non-controlling interest	(925)
Non-controlling interest	46,376
Saugatuck [Member]
Statement Line Items [Line Items]
Balance
Acquisition date fair values of non-controlling interests in subsidiaries	90
Fair value:
SalvaRx warrants vested upon acquisition
Vested portion of IOX stock options
Stock based compensation expense
Net loss attributable to non-controlling interest	(3)
Non-controlling interest	$ 87

Event After the Balance Sheet Date (Details) - Disposal of major subsidiary [member]		1 Months Ended
	Jul. 11, 2019	Dec. 23, 2019
Event After the Balance Sheet Date (Textual)
Agreement, description	The Company entered into an agreement with Fast Forward Innovations Limited ("Fast Forward") to purchase Intensity Holdings Limited ("IHL"), a wholly-owned subsidiary of Fast Forward. Portage has agreed to pay US $1,298,061 for IHL through the issuance of 12,980,610 common shares. The sole asset of IHL consists of 288,458 shares of the private company, Intensity. This transaction will increase Portage's ownership to 1,288,458 shares of Intensity (approximately 9.7% of the outstanding shares of Intensity.
Maturity date, description		The maturity date of $3.0 million SalvaRx Notes was extended to 2021.